ICD-10 · Primary diagnosis

Codes that cannot be a primary diagnosis

The 1603 ICD-10-CM codes CMS explicitly flags as unacceptable in the primary position, read from grouper v07.1.26.

OASIS-E2 v1.00.0 · ingested 2026-04-26

A claim whose principal diagnosis CMS will not accept comes back as a Return to Provider. Not denied — returned, so it can be corrected and resubmitted. The cost is the time the period sits unpaid while somebody finds a better code, which in an agency running a thin cash position is felt within a cycle.

There are two separate ways a code fails here, and they are worth keeping apart. The 1603 codes on this page carry an explicit CMS flag marking them unacceptable in the primary position. Separately, 30,902 of the 74,719 codes CMS publishes are assigned to no clinical group at all — roughly 41% — and a 30-day period cannot be grouped from one of those either.

Most of the codes below fall into recognisable families: external-cause codes that record how an injury happened, manifestation codes that require their underlying condition to be coded first, and codes too unspecified to describe a home health episode. If you are checking one code rather than browsing, the primary diagnosis checker answers it directly, including the codes with no clinical group.

The full list, by ICD-10-CM range

  • B950Streptococcus, group A, causing diseases classd elswhr
  • B951Streptococcus, group B, causing diseases classd elswhr
  • B952Enterococcus as the cause of diseases classified elsewhere
  • B953Streptococcus pneumoniae causing diseases classd elswhr
  • B954Oth streptococcus as the cause of diseases classd elswhr
  • B955Unsp streptococcus as the cause of diseases classd elswhr
  • B9561Methicillin suscep staph infct causing dis classd elswhr
  • B9562Methicillin resis staph infct causing diseases classd elswhr
  • B957Oth staphylococcus as the cause of diseases classd elswhr
  • B958Unsp staphylococcus as the cause of diseases classd elswhr
  • B960Mycoplasma pneumoniae as the cause of diseases classd elswhr
  • B961Klebsiella pneumoniae as the cause of diseases classd elswhr
  • B9620Unsp Escherichia coli as the cause of diseases classd elswhr
  • B9621Shig tox E coli [STEC] O157 causing diseases classd elswhr
  • B9622Oth shiga toxin E coli [STEC] causing diseases classd elswhr
  • B9623Unsp shig tox E coli [STEC] causing diseases classd elswhr
  • B9629Oth Escherichia coli as the cause of diseases classd elswhr
  • B963Hemophilus influenzae as the cause of diseases classd elswhr
  • B964Proteus (mirabilis) (morganii) causing dis classd elswhr
  • B965Pseudomonas (mallei) causing diseases classd elswhr
  • B966Bacteroides fragilis as the cause of diseases classd elswhr
  • B967Clostridium perfringens causing diseases classd elswhr
  • B9681Helicobacter pylori as the cause of diseases classd elswhr
  • B9682Vibrio vulnificus as the cause of diseases classd elswhr
  • B9683Acinetobacter baumannii causing diseases classd elswhr
  • B9689Oth bacterial agents as the cause of diseases classd elswhr
  • B970Adenovirus as the cause of diseases classified elsewhere
  • B9710Unsp enterovirus as the cause of diseases classd elswhr
  • B9711Coxsackievirus as the cause of diseases classified elsewhere
  • B9712Echovirus as the cause of diseases classified elsewhere
  • B9719Oth enterovirus as the cause of diseases classd elswhr
  • B9721SARS-associated coronavirus causing diseases classd elswhr
  • B9729Oth coronavirus as the cause of diseases classd elswhr
  • B9730Unsp retrovirus as the cause of diseases classd elswhr
  • B9731Lentivirus as the cause of diseases classified elsewhere
  • B9732Oncovirus as the cause of diseases classified elsewhere
  • B9733HTLV-I as the cause of diseases classified elsewhere
  • B9734HTLV-II as the cause of diseases classified elsewhere
  • B9735HIV 2 as the cause of diseases classified elsewhere
  • B9739Oth retrovirus as the cause of diseases classified elsewhere
  • B974Respiratory syncytial virus causing diseases classd elswhr
  • B975Reovirus as the cause of diseases classified elsewhere
  • B976Parvovirus as the cause of diseases classified elsewhere
  • B977Papillomavirus as the cause of diseases classified elsewhere
  • B9781Human metapneumovirus as the cause of diseases classd elswhr
  • B9789Oth viral agents as the cause of diseases classd elswhr
  • C802Malignant neoplasm associated with transplanted organ
  • D89810Acute graft-versus-host disease
  • D89811Chronic graft-versus-host disease
  • D89812Acute on chronic graft-versus-host disease
  • D89813Graft-versus-host disease, unspecified
  • D89831Cytokine release syndrome, grade 1
  • D89832Cytokine release syndrome, grade 2
  • D89833Cytokine release syndrome, grade 3
  • D89834Cytokine release syndrome, grade 4
  • D89835Cytokine release syndrome, grade 5
  • D89839Cytokine release syndrome, grade unspecified
  • E88AWasting disease (syndrome) due to underlying condition
  • F0670Mild neurocog disord d/t known physiol cond w/o beh distrb
  • F0671Mild neurocog disord d/t known physiol cond with beh distrb
  • F070Personality change due to known physiological condition
  • G731Lambert-Eaton syndrome in neoplastic disease
  • G9200Immune effor cell-associated neurotoxicity synd, grade unsp
  • G9201Immune effector cell-associated neurotoxicity synd, grade 1
  • G9202Immune effector cell-associated neurotoxicity synd, grade 2
  • G9203Immune effector cell-associated neurotoxicity synd, grade 3
  • G9204Immune effector cell-associated neurotoxicity synd, grade 4
  • G9205Immune effector cell-associated neurotoxicity synd, grade 5
  • H36811Nonproliferative sickle-cell retinopathy, right eye
  • H36812Nonproliferative sickle-cell retinopathy, left eye
  • H36813Nonproliferative sickle-cell retinopathy, bilateral
  • H36819Nonproliferative sickle-cell retinopathy, unspecified eye
  • H36821Proliferative sickle-cell retinopathy, right eye
  • H36822Proliferative sickle-cell retinopathy, left eye
  • H36823Proliferative sickle-cell retinopathy, bilateral
  • H36829Proliferative sickle-cell retinopathy, unspecified eye
  • I2582Chronic total occlusion of coronary artery
  • I2583Coronary atherosclerosis due to lipid rich plaque
  • I2584Coronary atherosclerosis due to calcified coronary lesion
  • I2601Septic pulmonary embolism with acute cor pulmonale
  • I2603Cement embolism of pulmonary artery with acute cor pulmonale
  • I2690Septic pulmonary embolism without acute cor pulmonale
  • I2695Cement embolism of pulm artery without acute cor pulmonale
  • I314Cardiac tamponade
  • I462Cardiac arrest due to underlying cardiac condition
  • I468Cardiac arrest due to other underlying condition
  • I7092Chronic total occlusion of artery of the extremities
  • I76Septic arterial embolism
  • J1282Pneumonia due to coronavirus disease 2019
  • J9312Secondary spontaneous pneumothorax
  • L490Exfoliatn due to erythemat cond w < 10 pct of body surface
  • L491Exfoliatn due to erythemat cond w 10-19 pct of body surface
  • L492Exfoliatn due to erythemat cond w 20-29 pct of body surface
  • L493Exfoliatn due to erythemat cond w 30-39 pct of body surface
  • L494Exfoliatn due to erythemat cond w 40-49 pct of body surface
  • L495Exfoliatn due to erythemat cond w 50-59 pct of body surface
  • L496Exfoliatn due to erythemat cond w 60-69 pct of body surface
  • L497Exfoliatn due to erythemat cond w 70-79 pct of body surface
  • L498Exfoliatn due to erythemat cond w 80-89 pct of body surface
  • L499Exfoliatn d/t erythemat cond w 90 or more pct of body surfc
  • M4010Other secondary kyphosis, site unspecified
  • M4012Other secondary kyphosis, cervical region
  • M4013Other secondary kyphosis, cervicothoracic region
  • M4014Other secondary kyphosis, thoracic region
  • M4015Other secondary kyphosis, thoracolumbar region
  • M4150Other secondary scoliosis, site unspecified
  • M4152Other secondary scoliosis, cervical region
  • M4153Other secondary scoliosis, cervicothoracic region
  • M4154Other secondary scoliosis, thoracic region
  • M4155Other secondary scoliosis, thoracolumbar region
  • M4156Other secondary scoliosis, lumbar region
  • M4157Other secondary scoliosis, lumbosacral region
  • O94Sequelae of comp of pregnancy, chldbrth, and the puerperium
  • R29700NIHSS score 0
  • R29701NIHSS score 1
  • R29702NIHSS score 2
  • R29703NIHSS score 3
  • R29704NIHSS score 4
  • R29705NIHSS score 5
  • R29706NIHSS score 6
  • R29707NIHSS score 7
  • R29708NIHSS score 8
  • R29709NIHSS score 9
  • R29710NIHSS score 10
  • R29711NIHSS score 11
  • R29712NIHSS score 12
  • R29713NIHSS score 13
  • R29714NIHSS score 14
  • R29715NIHSS score 15
  • R29716NIHSS score 16
  • R29717NIHSS score 17
  • R29718NIHSS score 18
  • R29719NIHSS score 19
  • R29720NIHSS score 20
  • R29721NIHSS score 21
  • R29722NIHSS score 22
  • R29723NIHSS score 23
  • R29724NIHSS score 24
  • R29725NIHSS score 25
  • R29726NIHSS score 26
  • R29727NIHSS score 27
  • R29728NIHSS score 28
  • R29729NIHSS score 29
  • R29730NIHSS score 30
  • R29731NIHSS score 31
  • R29732NIHSS score 32
  • R29733NIHSS score 33
  • R29734NIHSS score 34
  • R29735NIHSS score 35
  • R29736NIHSS score 36
  • R29737NIHSS score 37
  • R29738NIHSS score 38
  • R29739NIHSS score 39
  • R29740NIHSS score 40
  • R29741NIHSS score 41
  • R29742NIHSS score 42
  • R402110Coma scale, eyes open, never, unspecified time
  • R402111Coma scale, eyes open, never, in the field
  • R402112Coma scale, eyes open, never, EMR
  • R402113Coma scale, eyes open, never, at hospital admission
  • R402114Coma scale, eyes open, never, 24+hrs
  • R402120Coma scale, eyes open, to pain, unspecified time
  • R402121Coma scale, eyes open, to pain, in the field
  • R402122Coma scale, eyes open, to pain, EMR
  • R402123Coma scale, eyes open, to pain, at hospital admission
  • R402124Coma scale, eyes open, to pain, 24+hrs
  • R402130Coma scale, eyes open, to sound, unspecified time
  • R402131Coma scale, eyes open, to sound, in the field
  • R402132Coma scale, eyes open, to sound, EMR
  • R402133Coma scale, eyes open, to sound, at hospital admission
  • R402134Coma scale, eyes open, to sound, 24+hrs
  • R402140Coma scale, eyes open, spontaneous, unspecified time
  • R402141Coma scale, eyes open, spontaneous, in the field
  • R402142Coma scale, eyes open, spontaneous, EMR
  • R402143Coma scale, eyes open, spontaneous, at hospital admission
  • R402144Coma scale, eyes open, spontaneous, 24+hrs
  • R402210Coma scale, best verbal response, none, unspecified time
  • R402211Coma scale, best verbal response, none, in the field
  • R402212Coma scale, best verbal response, none, EMR
  • R402213Coma scale, best verbal response, none, admit
  • R402214Coma scale, best verbal response, none, 24+hrs
  • R402220Coma scale, best verb, incomprehensible words, unsp time
  • R402221Coma scale, best verb, incomprehensible words, in the field
  • R402222Coma scale, best verb, incomprehensible words, EMR
  • R402223Coma scale, best verb, incomprehensible words, admit
  • R402224Coma scale, best verb, incomprehensible words, 24+hrs
  • R402230Coma scale, best verb, inappropriate words, unsp time
  • R402231Coma scale, best verb, inappropriate words, in the field
  • R402232Coma scale, best verbal response, inappropriate words, EMR
  • R402233Coma scale, best verbal response, inappropriate words, admit
  • R402234Coma scale, best verb, inappropriate words, 24+hrs
  • R402240Coma scale, best verb, confused conversation, unsp time
  • R402241Coma scale, best verb, confused conversation, in the field
  • R402242Coma scale, best verbal response, confused conversation, EMR
  • R402243Coma scale, best verb, confused conversation, admit
  • R402244Coma scale, best verb, confused conversation, 24+hrs
  • R402250Coma scale, best verbal response, oriented, unspecified time
  • R402251Coma scale, best verbal response, oriented, in the field
  • R402252Coma scale, best verbal response, oriented, EMR
  • R402253Coma scale, best verbal response, oriented, admit
  • R402254Coma scale, best verbal response, oriented, 24+hrs
  • R402310Coma scale, best motor response, none, unspecified time
  • R402311Coma scale, best motor response, none, in the field
  • R402312Coma scale, best motor response, none, EMR
  • R402313Coma scale, best motor response, none, at hospital admission
  • R402314Coma scale, best motor response, none, 24+hrs
  • R402320Coma scale, best motor response, extension, unspecified time
  • R402321Coma scale, best motor response, extension, in the field
  • R402322Coma scale, best motor response, extension, EMR
  • R402323Coma scale, best motor response, extension, admit
  • R402324Coma scale, best motor response, extension, 24+hrs
  • R402330Coma scale, best motor, abnormal flexion, unspecified time
  • R402331Coma scale, best motor, abnormal flexion, in the field
  • R402332Coma scale, best motor response, abnormal flexion, EMR
  • R402333Coma scale, best motor response, abnormal flexion, admit
  • R402334Coma scale, best motor response, abnormal flexion, 24+hrs
  • R402340Coma scale, best motor, flexion withdrawal, unsp time
  • R402341Coma scale, best motor, flexion withdrawal, in the field
  • R402342Coma scale, best motor response, flexion withdrawal, EMR
  • R402343Coma scale, best motor response, flexion withdrawal, admit
  • R402344Coma scale, best motor response, flexion withdrawal, 24+hrs
  • R402350Coma scale, best motor response, localizes pain, unsp time
  • R402351Coma scale, best motor, localizes pain, in the field
  • R402352Coma scale, best motor response, localizes pain, EMR
  • R402353Coma scale, best motor response, localizes pain, admit
  • R402354Coma scale, best motor response, localizes pain, 24+hrs
  • R402360Coma scale, best motor response, obeys commands, unsp time
  • R402361Coma scale, best motor, obeys commands, in the field
  • R402362Coma scale, best motor response, obeys commands, EMR
  • R402363Coma scale, best motor response, obeys commands, admit
  • R402364Coma scale, best motor response, obeys commands, 24+hrs
  • R402410Glasgow coma scale score 13-15, unspecified time
  • R402411Glasgow coma scale score 13-15, in the field
  • R402412Glasgow coma scale score 13-15, EMR
  • R402413Glasgow coma scale score 13-15, at hospital admission
  • R402414Glasgow coma scale score 13-15, 24+hrs
  • R402420Glasgow coma scale score 9-12, unspecified time
  • R402421Glasgow coma scale score 9-12, in the field
  • R402422Glasgow coma scale score 9-12, EMR
  • R402423Glasgow coma scale score 9-12, at hospital admission
  • R402424Glasgow coma scale score 9-12, 24+hrs
  • R402430Glasgow coma scale score 3-8, unspecified time
  • R402431Glasgow coma scale score 3-8, in the field
  • R402432Glasgow coma scale score 3-8, EMR
  • R402433Glasgow coma scale score 3-8, at hospital admission
  • R402434Glasgow coma scale score 3-8, 24+hrs
  • R402440Other coma, without Glasgow, or w/part score, unsp time
  • R402441Other coma, without Glasgow, or w/part score, in the field
  • R402442Other coma, without documented Glasgow, or w/part score, EMR
  • R402443Other coma, without Glasgow, or w/part score, admit
  • R402444Other coma, without Glasgow, or w/part score, 24+hrs
  • R402ANontraumatic coma due to underlying condition
  • R6510SIRS of non-infectious origin w/o acute organ dysfunction
  • R6511SIRS of non-infectious origin w acute organ dysfunction
  • R6520Severe sepsis without septic shock
  • R6521Severe sepsis with septic shock
  • S06A0XATraumatic brain compression without herniation, init
  • S06A0XDTraumatic brain compression without herniation, subs
  • S06A0XSTraumatic brain compression without herniation, sequela
  • S06A1XATraumatic brain compression with herniation, init
  • S06A1XDTraumatic brain compression with herniation, subs
  • S06A1XSTraumatic brain compression with herniation, sequela
  • T360X5AAdverse effect of penicillins, initial encounter
  • T360X5DAdverse effect of penicillins, subsequent encounter
  • T360X5SAdverse effect of penicillins, sequela
  • T360X6AUnderdosing of penicillins, initial encounter
  • T360X6DUnderdosing of penicillins, subsequent encounter
  • T360X6SUnderdosing of penicillins, sequela
  • T361X5AAdverse effect of cephalospor/oth beta-lactm antibiot, init
  • T361X5DAdverse effect of cephalospor/oth beta-lactm antibiot, subs
  • T361X5SAdvrs effect of cephalospor/oth beta-lactm antibiot, sequela
  • T361X6AUnderdosing of cephalospor/oth beta-lactm antibiotics, init
  • T361X6DUnderdosing of cephalospor/oth beta-lactm antibiotics, subs
  • T361X6SUnderdosing of cephalospor/oth beta-lactm antibiot, sequela
  • T362X5AAdverse effect of chloramphenicol group, initial encounter
  • T362X5DAdverse effect of chloramphenicol group, subs encntr
  • T362X5SAdverse effect of chloramphenicol group, sequela
  • T362X6AUnderdosing of chloramphenicol group, initial encounter
  • T362X6DUnderdosing of chloramphenicol group, subsequent encounter
  • T362X6SUnderdosing of chloramphenicol group, sequela
  • T363X5AAdverse effect of macrolides, initial encounter
  • T363X5DAdverse effect of macrolides, subsequent encounter
  • T363X5SAdverse effect of macrolides, sequela
  • T363X6AUnderdosing of macrolides, initial encounter
  • T363X6DUnderdosing of macrolides, subsequent encounter
  • T363X6SUnderdosing of macrolides, sequela
  • T364X5AAdverse effect of tetracyclines, initial encounter
  • T364X5DAdverse effect of tetracyclines, subsequent encounter
  • T364X5SAdverse effect of tetracyclines, sequela
  • T364X6AUnderdosing of tetracyclines, initial encounter
  • T364X6DUnderdosing of tetracyclines, subsequent encounter
  • T364X6SUnderdosing of tetracyclines, sequela
  • T365X5AAdverse effect of aminoglycosides, initial encounter
  • T365X5DAdverse effect of aminoglycosides, subsequent encounter
  • T365X5SAdverse effect of aminoglycosides, sequela
  • T365X6AUnderdosing of aminoglycosides, initial encounter
  • T365X6DUnderdosing of aminoglycosides, subsequent encounter
  • T365X6SUnderdosing of aminoglycosides, sequela
  • T366X5AAdverse effect of rifampicins, initial encounter
  • T366X5DAdverse effect of rifampicins, subsequent encounter
  • T366X5SAdverse effect of rifampicins, sequela
  • T366X6AUnderdosing of rifampicins, initial encounter
  • T366X6DUnderdosing of rifampicins, subsequent encounter
  • T366X6SUnderdosing of rifampicins, sequela
  • T367X5AAdverse effect of antifungal antibiotics, sys used, init
  • T367X5DAdverse effect of antifungal antibiotics, sys used, subs
  • T367X5SAdverse effect of antifungal antibiotics, sys used, sequela
  • T367X6AUnderdosing of antifungal antibiotics, sys used, init
  • T367X6DUnderdosing of antifungal antibiotics, sys used, subs
  • T367X6SUnderdosing of antifungal antibiotics, sys used, sequela
  • T368X5AAdverse effect of other systemic antibiotics, init encntr
  • T368X5DAdverse effect of other systemic antibiotics, subs encntr
  • T368X5SAdverse effect of other systemic antibiotics, sequela
  • T368X6AUnderdosing of other systemic antibiotics, initial encounter
  • T368X6DUnderdosing of other systemic antibiotics, subs encntr
  • T368X6SUnderdosing of other systemic antibiotics, sequela
  • T3695XAAdverse effect of unsp systemic antibiotic, init encntr
  • T3695XDAdverse effect of unsp systemic antibiotic, subs encntr
  • T3695XSAdverse effect of unspecified systemic antibiotic, sequela
  • T3696XAUnderdosing of unspecified systemic antibiotic, init encntr
  • T3696XDUnderdosing of unspecified systemic antibiotic, subs encntr
  • T3696XSUnderdosing of unspecified systemic antibiotic, sequela
  • T36AX5AAdverse effect of fluoroquinolone antibiotics, init
  • T36AX5DAdverse effect of fluoroquinolone antibiotics, subs
  • T36AX5SAdverse effect of fluoroquinolone antibiotics, sequela
  • T36AX6AUnderdosing of fluoroquinolone antibiotics, init
  • T36AX6DUnderdosing of fluoroquinolone antibiotics, subs
  • T36AX6SUnderdosing of fluoroquinolone antibiotics, sequela
  • T370X5AAdverse effect of sulfonamides, initial encounter
  • T370X5DAdverse effect of sulfonamides, subsequent encounter
  • T370X5SAdverse effect of sulfonamides, sequela
  • T370X6AUnderdosing of sulfonamides, initial encounter
  • T370X6DUnderdosing of sulfonamides, subsequent encounter
  • T370X6SUnderdosing of sulfonamides, sequela
  • T371X5AAdverse effect of antimycobacterial drugs, initial encounter
  • T371X5DAdverse effect of antimycobacterial drugs, subs encntr
  • T371X5SAdverse effect of antimycobacterial drugs, sequela
  • T371X6AUnderdosing of antimycobacterial drugs, initial encounter
  • T371X6DUnderdosing of antimycobacterial drugs, subsequent encounter
  • T371X6SUnderdosing of antimycobacterial drugs, sequela
  • T372X5AAdvrs effect of antimalari/drugs acting on bld protzoa, init
  • T372X5DAdvrs effect of antimalari/drugs acting on bld protzoa, subs
  • T372X5SAdvrs effect of antimalari/drugs acting on bld protzoa, sqla
  • T372X6AUnderdosing of antimalari/drugs acting on bld protzoa, init
  • T372X6DUnderdosing of antimalari/drugs acting on bld protzoa, subs
  • T372X6SUndrdose of antimalari/drugs acting on bld protzoa, sequela
  • T373X5AAdverse effect of other antiprotozoal drugs, init encntr
  • T373X5DAdverse effect of other antiprotozoal drugs, subs encntr
  • T373X5SAdverse effect of other antiprotozoal drugs, sequela
  • T373X6AUnderdosing of other antiprotozoal drugs, initial encounter
  • T373X6DUnderdosing of other antiprotozoal drugs, subs encntr
  • T373X6SUnderdosing of other antiprotozoal drugs, sequela
  • T374X5AAdverse effect of anthelminthics, initial encounter
  • T374X5DAdverse effect of anthelminthics, subsequent encounter
  • T374X5SAdverse effect of anthelminthics, sequela
  • T374X6AUnderdosing of anthelminthics, initial encounter
  • T374X6DUnderdosing of anthelminthics, subsequent encounter
  • T374X6SUnderdosing of anthelminthics, sequela
  • T375X5AAdverse effect of antiviral drugs, initial encounter
  • T375X5DAdverse effect of antiviral drugs, subsequent encounter
  • T375X5SAdverse effect of antiviral drugs, sequela
  • T375X6AUnderdosing of antiviral drugs, initial encounter
  • T375X6DUnderdosing of antiviral drugs, subsequent encounter
  • T375X6SUnderdosing of antiviral drugs, sequela
  • T378X5AAdverse effect of systemic anti-infect/parasit, init
  • T378X5DAdverse effect of systemic anti-infect/parasit, subs
  • T378X5SAdverse effect of systemic anti-infect/parasit, sequela
  • T378X6AUnderdosing of systemic anti-infect/parasit, init
  • T378X6DUnderdosing of systemic anti-infect/parasit, subs
  • T378X6SUnderdosing of systemic anti-infect/parasit, sequela
  • T3795XAAdvrs effect of unsp sys anti-infect and antiparasitic, init
  • T3795XDAdvrs effect of unsp sys anti-infect and antiparasitic, subs
  • T3795XSAdvrs effect of unsp sys anti-infect and antiparasitic, sqla
  • T3796XAUnderdosing of unsp systemic anti-infect/parasit, init
  • T3796XDUnderdosing of unsp systemic anti-infect/parasit, subs
  • T3796XSUnderdosing of unsp systemic anti-infect/parasit, sequela
  • T380X5AAdverse effect of glucocort/synth analog, init
  • T380X5DAdverse effect of glucocort/synth analog, subs
  • T380X5SAdverse effect of glucocort/synth analog, sequela
  • T380X6AUnderdosing of glucocorticoids and synthetic analogues, init
  • T380X6DUnderdosing of glucocorticoids and synthetic analogues, subs
  • T380X6SUnderdosing of glucocort/synth analog, sequela
  • T381X5AAdverse effect of thyroid hormones and substitutes, init
  • T381X5DAdverse effect of thyroid hormones and substitutes, subs
  • T381X5SAdverse effect of thyroid hormones and substitutes, sequela
  • T381X6AUnderdosing of thyroid hormones and substitutes, init encntr
  • T381X6DUnderdosing of thyroid hormones and substitutes, subs encntr
  • T381X6SUnderdosing of thyroid hormones and substitutes, sequela
  • T382X5AAdverse effect of antithyroid drugs, initial encounter
  • T382X5DAdverse effect of antithyroid drugs, subsequent encounter
  • T382X5SAdverse effect of antithyroid drugs, sequela
  • T382X6AUnderdosing of antithyroid drugs, initial encounter
  • T382X6DUnderdosing of antithyroid drugs, subsequent encounter
  • T382X6SUnderdosing of antithyroid drugs, sequela
  • T383X5AAdverse effect of insulin and oral hypoglycemic drugs, init
  • T383X5DAdverse effect of insulin and oral hypoglycemic drugs, subs
  • T383X5SAdvrs effect of insulin and oral hypoglycemic drugs, sequela
  • T383X6AUnderdosing of insulin and oral hypoglycemic drugs, init
  • T383X6DUnderdosing of insulin and oral hypoglycemic drugs, subs
  • T383X6SUnderdosing of insulin and oral hypoglycemic drugs, sequela
  • T384X5AAdverse effect of oral contraceptives, initial encounter
  • T384X5DAdverse effect of oral contraceptives, subsequent encounter
  • T384X5SAdverse effect of oral contraceptives, sequela
  • T384X6AUnderdosing of oral contraceptives, initial encounter
  • T384X6DUnderdosing of oral contraceptives, subsequent encounter
  • T384X6SUnderdosing of oral contraceptives, sequela
  • T385X5AAdverse effect of oth estrogens and progestogens, init
  • T385X5DAdverse effect of oth estrogens and progestogens, subs
  • T385X5SAdverse effect of other estrogens and progestogens, sequela
  • T385X6AUnderdosing of other estrogens and progestogens, init encntr
  • T385X6DUnderdosing of other estrogens and progestogens, subs encntr
  • T385X6SUnderdosing of other estrogens and progestogens, sequela
  • T386X5AAdverse effect of antigonadtr/antiestr/antiandrg, NEC, init
  • T386X5DAdverse effect of antigonadtr/antiestr/antiandrg, NEC, subs
  • T386X5SAdvrs effect of antigonadtr/antiestr/antiandrg, NEC, sequela
  • T386X6AUnderdosing of antigonadtr/antiestr/antiandrg, NEC, init
  • T386X6DUnderdosing of antigonadtr/antiestr/antiandrg, NEC, subs
  • T386X6SUnderdosing of antigonadtr/antiestr/antiandrg, NEC, sequela
  • T387X5AAdverse effect of androgens and anabolic congeners, init
  • T387X5DAdverse effect of androgens and anabolic congeners, subs
  • T387X5SAdverse effect of androgens and anabolic congeners, sequela
  • T387X6AUnderdosing of androgens and anabolic congeners, init encntr
  • T387X6DUnderdosing of androgens and anabolic congeners, subs encntr
  • T387X6SUnderdosing of androgens and anabolic congeners, sequela
  • T38805AAdverse effect of unsp hormones and synthetic sub, init
  • T38805DAdverse effect of unsp hormones and synthetic sub, subs
  • T38805SAdverse effect of unsp hormones and synthetic sub, sequela
  • T38806AUnderdosing of unsp hormones and synthetic substitutes, init
  • T38806DUnderdosing of unsp hormones and synthetic substitutes, subs
  • T38806SUnderdosing of unsp hormones and synthetic sub, sequela
  • T38815AAdverse effect of anterior pituitary hormones, init encntr
  • T38815DAdverse effect of anterior pituitary hormones, subs encntr
  • T38815SAdverse effect of anterior pituitary hormones, sequela
  • T38816AUnderdosing of anterior pituitary hormones, init encntr
  • T38816DUnderdosing of anterior pituitary hormones, subs encntr
  • T38816SUnderdosing of anterior pituitary hormones, sequela
  • T38895AAdverse effect of hormones and synthetic substitutes, init
  • T38895DAdverse effect of hormones and synthetic substitutes, subs
  • T38895SAdverse effect of hormones and synthetic sub, sequela
  • T38896AUnderdosing of oth hormones and synthetic substitutes, init
  • T38896DUnderdosing of oth hormones and synthetic substitutes, subs
  • T38896SUnderdosing of hormones and synthetic substitutes, sequela
  • T38905AAdverse effect of unsp hormone antagonists, init encntr
  • T38905DAdverse effect of unsp hormone antagonists, subs encntr
  • T38905SAdverse effect of unspecified hormone antagonists, sequela
  • T38906AUnderdosing of unspecified hormone antagonists, init encntr
  • T38906DUnderdosing of unspecified hormone antagonists, subs encntr
  • T38906SUnderdosing of unspecified hormone antagonists, sequela
  • T38995AAdverse effect of other hormone antagonists, init encntr
  • T38995DAdverse effect of other hormone antagonists, subs encntr
  • T38995SAdverse effect of other hormone antagonists, sequela
  • T38996AUnderdosing of other hormone antagonists, initial encounter
  • T38996DUnderdosing of other hormone antagonists, subs encntr
  • T38996SUnderdosing of other hormone antagonists, sequela
  • T39015AAdverse effect of aspirin, initial encounter
  • T39015DAdverse effect of aspirin, subsequent encounter
  • T39015SAdverse effect of aspirin, sequela
  • T39016AUnderdosing of aspirin, initial encounter
  • T39016DUnderdosing of aspirin, subsequent encounter
  • T39016SUnderdosing of aspirin, sequela
  • T39095AAdverse effect of salicylates, initial encounter
  • T39095DAdverse effect of salicylates, subsequent encounter
  • T39095SAdverse effect of salicylates, sequela
  • T39096AUnderdosing of salicylates, initial encounter
  • T39096DUnderdosing of salicylates, subsequent encounter
  • T39096SUnderdosing of salicylates, sequela
  • T391X5AAdverse effect of 4-Aminophenol derivatives, init encntr
  • T391X5DAdverse effect of 4-Aminophenol derivatives, subs encntr
  • T391X5SAdverse effect of 4-Aminophenol derivatives, sequela
  • T391X6AUnderdosing of 4-Aminophenol derivatives, initial encounter
  • T391X6DUnderdosing of 4-Aminophenol derivatives, subs encntr
  • T391X6SUnderdosing of 4-Aminophenol derivatives, sequela
  • T392X5AAdverse effect of pyrazolone derivatives, initial encounter
  • T392X5DAdverse effect of pyrazolone derivatives, subs encntr
  • T392X5SAdverse effect of pyrazolone derivatives, sequela
  • T392X6AUnderdosing of pyrazolone derivatives, initial encounter
  • T392X6DUnderdosing of pyrazolone derivatives, subsequent encounter
  • T392X6SUnderdosing of pyrazolone derivatives, sequela
  • T39315AAdverse effect of propionic acid derivatives, init encntr
  • T39315DAdverse effect of propionic acid derivatives, subs encntr
  • T39315SAdverse effect of propionic acid derivatives, sequela
  • T39316AUnderdosing of propionic acid derivatives, initial encounter
  • T39316DUnderdosing of propionic acid derivatives, subs encntr
  • T39316SUnderdosing of propionic acid derivatives, sequela
  • T39395AAdverse effect of nonsteroidal anti-inflammatory drugs, init
  • T39395DAdverse effect of nonsteroidal anti-inflammatory drugs, subs
  • T39395SAdverse effect of nonsteroidal anti-inflam drugs, sequela
  • T39396AUnderdosing of nonsteroidal anti-inflammatory drugs, init
  • T39396DUnderdosing of nonsteroidal anti-inflammatory drugs, subs
  • T39396SUnderdosing of nonsteroidal anti-inflammatory drugs, sequela
  • T394X5AAdverse effect of antirheumatics, NEC, init
  • T394X5DAdverse effect of antirheumatics, NEC, subs
  • T394X5SAdverse effect of antirheumatics, NEC, sequela
  • T394X6AUnderdosing of antirheumatics, NEC, init
  • T394X6DUnderdosing of antirheumatics, NEC, subs
  • T394X6SUnderdosing of antirheumatics, NEC, sequela
  • T398X5AAdverse effect of nonopioid analges/antipyret, NEC, init
  • T398X5DAdverse effect of nonopioid analges/antipyret, NEC, subs
  • T398X5SAdverse effect of nonopioid analges/antipyret, NEC, sequela
  • T398X6AUnderdosing of nonopioid analges/antipyret, NEC, init
  • T398X6DUnderdosing of nonopioid analges/antipyret, NEC, subs
  • T398X6SUnderdosing of nonopioid analges/antipyret, NEC, sequela
  • T3995XAAdverse effect of unsp nonopi analgs/antipyr/antirheu, init
  • T3995XDAdverse effect of unsp nonopi analgs/antipyr/antirheu, subs
  • T3995XSAdvrs effect of unsp nonopi analgs/antipyr/antirheu, sequela
  • T3996XAUnderdosing of unsp nonopi analgs/antipyr/antirheu, init
  • T3996XDUnderdosing of unsp nonopi analgs/antipyr/antirheu, subs
  • T3996XSUnderdosing of unsp nonopi analgs/antipyr/antirheu, sequela
  • T400X5AAdverse effect of opium, initial encounter
  • T400X5DAdverse effect of opium, subsequent encounter
  • T400X5SAdverse effect of opium, sequela
  • T400X6AUnderdosing of opium, initial encounter
  • T400X6DUnderdosing of opium, subsequent encounter
  • T400X6SUnderdosing of opium, sequela
  • T402X5AAdverse effect of other opioids, initial encounter
  • T402X5DAdverse effect of other opioids, subsequent encounter
  • T402X5SAdverse effect of other opioids, sequela
  • T402X6AUnderdosing of other opioids, initial encounter
  • T402X6DUnderdosing of other opioids, subsequent encounter
  • T402X6SUnderdosing of other opioids, sequela
  • T403X5AAdverse effect of methadone, initial encounter
  • T403X5DAdverse effect of methadone, subsequent encounter
  • T403X5SAdverse effect of methadone, sequela
  • T403X6AUnderdosing of methadone, initial encounter
  • T403X6DUnderdosing of methadone, subsequent encounter
  • T403X6SUnderdosing of methadone, sequela
  • T40415AAdverse effect of fentanyl or fentanyl analogs, init
  • T40415DAdverse effect of fentanyl or fentanyl analogs, subs
  • T40415SAdverse effect of fentanyl or fentanyl analogs, sequela
  • T40416AUnderdosing of fentanyl or fentanyl analogs, init
  • T40416DUnderdosing of fentanyl or fentanyl analogs, subs
  • T40416SUnderdosing of fentanyl or fentanyl analogs, sequela
  • T40425AAdverse effect of tramadol, initial encounter
  • T40425DAdverse effect of tramadol, subsequent encounter
  • T40425SAdverse effect of tramadol, sequela
  • T40426AUnderdosing of tramadol, initial encounter
  • T40426DUnderdosing of tramadol, subsequent encounter
  • T40426SUnderdosing of tramadol, sequela
  • T40495AAdverse effect of other synthetic narcotics, init
  • T40495DAdverse effect of other synthetic narcotics, subs
  • T40495SAdverse effect of other synthetic narcotics, sequela
  • T40496AUnderdosing of other synthetic narcotics, initial encounter
  • T40496DUnderdosing of other synthetic narcotics, subs
  • T40496SUnderdosing of other synthetic narcotics, sequela
  • T405X5AAdverse effect of cocaine, initial encounter
  • T405X5DAdverse effect of cocaine, subsequent encounter
  • T405X5SAdverse effect of cocaine, sequela
  • T405X6AUnderdosing of cocaine, initial encounter
  • T405X6DUnderdosing of cocaine, subsequent encounter
  • T405X6SUnderdosing of cocaine, sequela
  • T40605AAdverse effect of unspecified narcotics, initial encounter
  • T40605DAdverse effect of unspecified narcotics, subs encntr
  • T40605SAdverse effect of unspecified narcotics, sequela
  • T40606AUnderdosing of unspecified narcotics, initial encounter
  • T40606DUnderdosing of unspecified narcotics, subsequent encounter
  • T40606SUnderdosing of unspecified narcotics, sequela
  • T40695AAdverse effect of other narcotics, initial encounter
  • T40695DAdverse effect of other narcotics, subsequent encounter
  • T40695SAdverse effect of other narcotics, sequela
  • T40696AUnderdosing of other narcotics, initial encounter
  • T40696DUnderdosing of other narcotics, subsequent encounter
  • T40696SUnderdosing of other narcotics, sequela
  • T40715AAdverse effect of cannabis, initial encounter
  • T40715DAdverse effect of cannabis, subsequent encounter
  • T40715SAdverse effect of cannabis, sequela
  • T40716AUnderdosing of cannabis, initial encounter
  • T40716DUnderdosing of cannabis, subsequent encounter
  • T40716SUnderdosing of cannabis, sequela
  • T40725AAdverse effect of synthetic cannabinoids, initial encounter
  • T40725DAdverse effect of synthetic cannabinoids, subs
  • T40725SAdverse effect of synthetic cannabinoids, sequela
  • T40726AUnderdosing of synthetic cannabinoids, initial encounter
  • T40726DUnderdosing of synthetic cannabinoids, subsequent encounter
  • T40726SUnderdosing of synthetic cannabinoids, sequela
  • T40905AAdverse effect of unspecified psychodysleptics, init encntr
  • T40905DAdverse effect of unspecified psychodysleptics, subs encntr
  • T40905SAdverse effect of unspecified psychodysleptics, sequela
  • T40906AUnderdosing of unspecified psychodysleptics, init
  • T40906DUnderdosing of unspecified psychodysleptics, subs
  • T40906SUnderdosing of unspecified psychodysleptics, sequela
  • T40995AAdverse effect of other psychodysleptics, initial encounter
  • T40995DAdverse effect of other psychodysleptics, subs encntr
  • T40995SAdverse effect of other psychodysleptics, sequela
  • T40996AUnderdosing of other psychodysleptics, initial encounter
  • T40996DUnderdosing of other psychodysleptics, subsequent encounter
  • T40996SUnderdosing of other psychodysleptics, sequela
  • T410X5AAdverse effect of inhaled anesthetics, initial encounter
  • T410X5DAdverse effect of inhaled anesthetics, subsequent encounter
  • T410X5SAdverse effect of inhaled anesthetics, sequela
  • T410X6AUnderdosing of inhaled anesthetics, initial encounter
  • T410X6DUnderdosing of inhaled anesthetics, subsequent encounter
  • T410X6SUnderdosing of inhaled anesthetics, sequela
  • T411X5AAdverse effect of intravenous anesthetics, initial encounter
  • T411X5DAdverse effect of intravenous anesthetics, subs encntr
  • T411X5SAdverse effect of intravenous anesthetics, sequela
  • T411X6AUnderdosing of intravenous anesthetics, initial encounter
  • T411X6DUnderdosing of intravenous anesthetics, subsequent encounter
  • T411X6SUnderdosing of intravenous anesthetics, sequela
  • T41205AAdverse effect of unsp general anesthetics, init encntr
  • T41205DAdverse effect of unsp general anesthetics, subs encntr
  • T41205SAdverse effect of unspecified general anesthetics, sequela
  • T41206AUnderdosing of unspecified general anesthetics, init encntr
  • T41206DUnderdosing of unspecified general anesthetics, subs encntr
  • T41206SUnderdosing of unspecified general anesthetics, sequela
  • T41295AAdverse effect of other general anesthetics, init encntr
  • T41295DAdverse effect of other general anesthetics, subs encntr
  • T41295SAdverse effect of other general anesthetics, sequela
  • T41296AUnderdosing of other general anesthetics, initial encounter
  • T41296DUnderdosing of other general anesthetics, subs encntr
  • T41296SUnderdosing of other general anesthetics, sequela
  • T413X5AAdverse effect of local anesthetics, initial encounter
  • T413X5DAdverse effect of local anesthetics, subsequent encounter
  • T413X5SAdverse effect of local anesthetics, sequela
  • T413X6AUnderdosing of local anesthetics, initial encounter
  • T413X6DUnderdosing of local anesthetics, subsequent encounter
  • T413X6SUnderdosing of local anesthetics, sequela
  • T4145XAAdverse effect of unspecified anesthetic, initial encounter
  • T4145XDAdverse effect of unspecified anesthetic, subs encntr
  • T4145XSAdverse effect of unspecified anesthetic, sequela
  • T4146XAUnderdosing of unspecified anesthetics, initial encounter
  • T4146XDUnderdosing of unspecified anesthetics, subsequent encounter
  • T4146XSUnderdosing of unspecified anesthetics, sequela
  • T415X5AAdverse effect of therapeutic gases, initial encounter
  • T415X5DAdverse effect of therapeutic gases, subsequent encounter
  • T415X5SAdverse effect of therapeutic gases, sequela
  • T415X6AUnderdosing of therapeutic gases, initial encounter
  • T415X6DUnderdosing of therapeutic gases, subsequent encounter
  • T415X6SUnderdosing of therapeutic gases, sequela
  • T420X5AAdverse effect of hydantoin derivatives, initial encounter
  • T420X5DAdverse effect of hydantoin derivatives, subs encntr
  • T420X5SAdverse effect of hydantoin derivatives, sequela
  • T420X6AUnderdosing of hydantoin derivatives, initial encounter
  • T420X6DUnderdosing of hydantoin derivatives, subsequent encounter
  • T420X6SUnderdosing of hydantoin derivatives, sequela
  • T421X5AAdverse effect of iminostilbenes, initial encounter
  • T421X5DAdverse effect of iminostilbenes, subsequent encounter
  • T421X5SAdverse effect of iminostilbenes, sequela
  • T421X6AUnderdosing of iminostilbenes, initial encounter
  • T421X6DUnderdosing of iminostilbenes, subsequent encounter
  • T421X6SUnderdosing of iminostilbenes, sequela
  • T422X5AAdverse effect of succinimides and oxazolidinediones, init
  • T422X5DAdverse effect of succinimides and oxazolidinediones, subs
  • T422X5SAdvrs effect of succinimides and oxazolidinediones, sequela
  • T422X6AUnderdosing of succinimides and oxazolidinediones, init
  • T422X6DUnderdosing of succinimides and oxazolidinediones, subs
  • T422X6SUnderdosing of succinimides and oxazolidinediones, sequela
  • T423X5AAdverse effect of barbiturates, initial encounter
  • T423X5DAdverse effect of barbiturates, subsequent encounter
  • T423X5SAdverse effect of barbiturates, sequela
  • T423X6AUnderdosing of barbiturates, initial encounter
  • T423X6DUnderdosing of barbiturates, subsequent encounter
  • T423X6SUnderdosing of barbiturates, sequela
  • T424X5AAdverse effect of benzodiazepines, initial encounter
  • T424X5DAdverse effect of benzodiazepines, subsequent encounter
  • T424X5SAdverse effect of benzodiazepines, sequela
  • T424X6AUnderdosing of benzodiazepines, initial encounter
  • T424X6DUnderdosing of benzodiazepines, subsequent encounter
  • T424X6SUnderdosing of benzodiazepines, sequela
  • T425X5AAdverse effect of mixed antiepileptics, initial encounter
  • T425X5DAdverse effect of mixed antiepileptics, subsequent encounter
  • T425X5SAdverse effect of mixed antiepileptics, sequela
  • T425X6AUnderdosing of mixed antiepileptics, initial encounter
  • T425X6DUnderdosing of mixed antiepileptics, subsequent encounter
  • T425X6SUnderdosing of mixed antiepileptics, sequela
  • T426X5AAdverse effect of antiepileptic and sed-hypntc drugs, init
  • T426X5DAdverse effect of antiepileptic and sed-hypntc drugs, subs
  • T426X5SAdverse effect of antieplptc and sed-hypntc drugs, sequela
  • T426X6AUnderdosing of antiepileptic and sed-hypntc drugs, init
  • T426X6DUnderdosing of antiepileptic and sed-hypntc drugs, subs
  • T426X6SUnderdosing of antiepileptic and sed-hypntc drugs, sequela
  • T4275XAAdverse effect of unsp antieplptc and sed-hypntc drugs, init
  • T4275XDAdverse effect of unsp antieplptc and sed-hypntc drugs, subs
  • T4275XSAdvrs effect of unsp antieplptc and sed-hypntc drugs, sqla
  • T4276XAUnderdosing of unsp antiepileptic and sed-hypntc drugs, init
  • T4276XDUnderdosing of unsp antiepileptic and sed-hypntc drugs, subs
  • T4276XSUnderdosing of unsp antieplptc and sed-hypntc drugs, sequela
  • T428X5AAdverse effect of antiparkns drug/centr musc-tone depr, init
  • T428X5DAdverse effect of antiparkns drug/centr musc-tone depr, subs
  • T428X5SAdvrs effect of antiparkns drug/centr musc-tone depr, sqla
  • T428X6AUnderdosing of antiparkns drug/centr muscle-tone depr, init
  • T428X6DUnderdosing of antiparkns drug/centr muscle-tone depr, subs
  • T428X6SUnderdosing of antiparkns drug/centr musc-tone depr, sequela
  • T43015AAdverse effect of tricyclic antidepressants, init encntr
  • T43015DAdverse effect of tricyclic antidepressants, subs encntr
  • T43015SAdverse effect of tricyclic antidepressants, sequela
  • T43016AUnderdosing of tricyclic antidepressants, initial encounter
  • T43016DUnderdosing of tricyclic antidepressants, subs encntr
  • T43016SUnderdosing of tricyclic antidepressants, sequela
  • T43025AAdverse effect of tetracyclic antidepressants, init encntr
  • T43025DAdverse effect of tetracyclic antidepressants, subs encntr
  • T43025SAdverse effect of tetracyclic antidepressants, sequela
  • T43026AUnderdosing of tetracyclic antidepressants, init encntr
  • T43026DUnderdosing of tetracyclic antidepressants, subs encntr
  • T43026SUnderdosing of tetracyclic antidepressants, sequela
  • T431X5AAdverse effect of MAO inhib antidepressants, init
  • T431X5DAdverse effect of MAO inhib antidepressants, subs
  • T431X5SAdverse effect of MAO inhib antidepressants, sequela
  • T431X6AUnderdosing of MAO inhib antidepressants, init
  • T431X6DUnderdosing of MAO inhib antidepressants, subs
  • T431X6SUnderdosing of MAO inhib antidepressants, sequela
  • T43205AAdverse effect of unspecified antidepressants, init encntr
  • T43205DAdverse effect of unspecified antidepressants, subs encntr
  • T43205SAdverse effect of unspecified antidepressants, sequela
  • T43206AUnderdosing of unspecified antidepressants, init encntr
  • T43206DUnderdosing of unspecified antidepressants, subs encntr
  • T43206SUnderdosing of unspecified antidepressants, sequela
  • T43215AAdvrs effect of slctv seroton/norepineph reup inhibtr, init
  • T43215DAdvrs effect of slctv seroton/norepineph reup inhibtr, subs
  • T43215SAdvrs effect of slctv seroton/norepineph reup inhibtr, sqla
  • T43216AUndrdose of selective seroton/norepineph reup inhibtr, init
  • T43216DUndrdose of selective seroton/norepineph reup inhibtr, subs
  • T43216SUndrdose of slctv seroton/norepineph reup inhibtr, sequela
  • T43225AAdverse effect of selective serotonin reuptake inhibtr, init
  • T43225DAdverse effect of selective serotonin reuptake inhibtr, subs
  • T43225SAdverse effect of slctv serotonin reuptake inhibtr, sequela
  • T43226AUnderdosing of selective serotonin reuptake inhibitors, init
  • T43226DUnderdosing of selective serotonin reuptake inhibitors, subs
  • T43226SUndrdose of selective serotonin reuptake inhibitors, sequela
  • T43295AAdverse effect of other antidepressants, initial encounter
  • T43295DAdverse effect of other antidepressants, subs encntr
  • T43295SAdverse effect of other antidepressants, sequela
  • T43296AUnderdosing of other antidepressants, initial encounter
  • T43296DUnderdosing of other antidepressants, subsequent encounter
  • T43296SUnderdosing of other antidepressants, sequela
  • T433X5AAdverse effect of phenothiazine antipsychot/neurolept, init
  • T433X5DAdverse effect of phenothiazine antipsychot/neurolept, subs
  • T433X5SAdverse effect of phenothiaz antipsychot/neurolept, sequela
  • T433X6AUnderdosing of phenothiazine antipsychot/neurolept, init
  • T433X6DUnderdosing of phenothiazine antipsychot/neurolept, subs
  • T433X6SUnderdosing of phenothiazine antipsychot/neurolept, sequela
  • T434X5AAdverse effect of butyrophen/thiothixen neuroleptics, init
  • T434X5DAdverse effect of butyrophen/thiothixen neuroleptics, subs
  • T434X5SAdverse effect of butyrophen/thiothixen neuroleptc, sequela
  • T434X6AUnderdosing of butyrophen/thiothixen neuroleptics, init
  • T434X6DUnderdosing of butyrophen/thiothixen neuroleptics, subs
  • T434X6SUnderdosing of butyrophen/thiothixen neuroleptics, sequela
  • T43505AAdverse effect of unsp antipsychotics and neuroleptics, init
  • T43505DAdverse effect of unsp antipsychotics and neuroleptics, subs
  • T43505SAdverse effect of unsp antipsychot/neurolept, sequela
  • T43506AUnderdosing of unsp antipsychotics and neuroleptics, init
  • T43506DUnderdosing of unsp antipsychotics and neuroleptics, subs
  • T43506SUnderdosing of unsp antipsychotics and neuroleptics, sequela
  • T43595AAdverse effect of oth antipsychotics and neuroleptics, init
  • T43595DAdverse effect of oth antipsychotics and neuroleptics, subs
  • T43595SAdverse effect of antipsychotics and neuroleptics, sequela
  • T43596AUnderdosing of oth antipsychotics and neuroleptics, init
  • T43596DUnderdosing of oth antipsychotics and neuroleptics, subs
  • T43596SUnderdosing of oth antipsychotics and neuroleptics, sequela
  • T43605AAdverse effect of unspecified psychostimulants, init encntr
  • T43605DAdverse effect of unspecified psychostimulants, subs encntr
  • T43605SAdverse effect of unspecified psychostimulants, sequela
  • T43606AUnderdosing of unspecified psychostimulants, init encntr
  • T43606DUnderdosing of unspecified psychostimulants, subs encntr
  • T43606SUnderdosing of unspecified psychostimulants, sequela
  • T43615AAdverse effect of caffeine, initial encounter
  • T43615DAdverse effect of caffeine, subsequent encounter
  • T43615SAdverse effect of caffeine, sequela
  • T43616AUnderdosing of caffeine, initial encounter
  • T43616DUnderdosing of caffeine, subsequent encounter
  • T43616SUnderdosing of caffeine, sequela
  • T43625AAdverse effect of amphetamines, initial encounter
  • T43625DAdverse effect of amphetamines, subsequent encounter
  • T43625SAdverse effect of amphetamines, sequela
  • T43626AUnderdosing of amphetamines, initial encounter
  • T43626DUnderdosing of amphetamines, subsequent encounter
  • T43626SUnderdosing of amphetamines, sequela
  • T43635AAdverse effect of methylphenidate, initial encounter
  • T43635DAdverse effect of methylphenidate, subsequent encounter
  • T43635SAdverse effect of methylphenidate, sequela
  • T43636AUnderdosing of methylphenidate, initial encounter
  • T43636DUnderdosing of methylphenidate, subsequent encounter
  • T43636SUnderdosing of methylphenidate, sequela
  • T43655AAdverse effect of methamphetamines, initial encounter
  • T43655DAdverse effect of methamphetamines, subsequent encounter
  • T43655SAdverse effect of methamphetamines, sequela
  • T43656AUnderdosing of methamphetamines, initial encounter
  • T43656DUnderdosing of methamphetamines, subsequent encounter
  • T43656SUnderdosing of methamphetamines, sequela
  • T43695AAdverse effect of other psychostimulants, initial encounter
  • T43695DAdverse effect of other psychostimulants, subs encntr
  • T43695SAdverse effect of other psychostimulants, sequela
  • T43696AUnderdosing of other psychostimulants, initial encounter
  • T43696DUnderdosing of other psychostimulants, subsequent encounter
  • T43696SUnderdosing of other psychostimulants, sequela
  • T438X5AAdverse effect of other psychotropic drugs, init encntr
  • T438X5DAdverse effect of other psychotropic drugs, subs encntr
  • T438X5SAdverse effect of other psychotropic drugs, sequela
  • T438X6AUnderdosing of other psychotropic drugs, initial encounter
  • T438X6DUnderdosing of other psychotropic drugs, subs encntr
  • T438X6SUnderdosing of other psychotropic drugs, sequela
  • T4395XAAdverse effect of unspecified psychotropic drug, init encntr
  • T4395XDAdverse effect of unspecified psychotropic drug, subs encntr
  • T4395XSAdverse effect of unspecified psychotropic drug, sequela
  • T4396XAUnderdosing of unspecified psychotropic drug, init encntr
  • T4396XDUnderdosing of unspecified psychotropic drug, subs encntr
  • T4396XSUnderdosing of unspecified psychotropic drug, sequela
  • T440X5AAdverse effect of anticholinesterase agents, init encntr
  • T440X5DAdverse effect of anticholinesterase agents, subs encntr
  • T440X5SAdverse effect of anticholinesterase agents, sequela
  • T440X6AUnderdosing of anticholinesterase agents, initial encounter
  • T440X6DUnderdosing of anticholinesterase agents, subs encntr
  • T440X6SUnderdosing of anticholinesterase agents, sequela
  • T441X5AAdverse effect of other parasympathomimetics, init encntr
  • T441X5DAdverse effect of other parasympathomimetics, subs encntr
  • T441X5SAdverse effect of other parasympathomimetics, sequela
  • T441X6AUnderdosing of other parasympathomimetics, initial encounter
  • T441X6DUnderdosing of other parasympath, subsequent encounter
  • T441X6SUnderdosing of other parasympathomimetics, sequela
  • T442X5AAdverse effect of ganglionic blocking drugs, init encntr
  • T442X5DAdverse effect of ganglionic blocking drugs, subs encntr
  • T442X5SAdverse effect of ganglionic blocking drugs, sequela
  • T442X6AUnderdosing of ganglionic blocking drugs, initial encounter
  • T442X6DUnderdosing of ganglionic blocking drugs, subs encntr
  • T442X6SUnderdosing of ganglionic blocking drugs, sequela
  • T443X5AAdverse effect of parasympatholytics and spasmolytics, init
  • T443X5DAdverse effect of parasympatholytics and spasmolytics, subs
  • T443X5SAdverse effect of parasympath and spasmolytics, sequela
  • T443X6AUnderdosing of oth parasympatholytics and spasmolytics, init
  • T443X6DUnderdosing of oth parasympatholytics and spasmolytics, subs
  • T443X6SUnderdosing of parasympatholytics and spasmolytics, sequela
  • T444X5AAdverse effect of predom alpha-adrenocpt agonists, init
  • T444X5DAdverse effect of predom alpha-adrenocpt agonists, subs
  • T444X5SAdverse effect of predom alpha-adrenocpt agonists, sequela
  • T444X6AUnderdosing of predominantly alpha-adrenocpt agonists, init
  • T444X6DUnderdosing of predominantly alpha-adrenocpt agonists, subs
  • T444X6SUnderdosing of predom alpha-adrenocpt agonists, sequela
  • T445X5AAdverse effect of predom beta-adrenocpt agonists, init
  • T445X5DAdverse effect of predom beta-adrenocpt agonists, subs
  • T445X5SAdverse effect of predom beta-adrenocpt agonists, sequela
  • T445X6AUnderdosing of predominantly beta-adrenocpt agonists, init
  • T445X6DUnderdosing of predominantly beta-adrenocpt agonists, subs
  • T445X6SUnderdosing of predom beta-adrenocpt agonists, sequela
  • T446X5AAdverse effect of alpha-adrenoreceptor antagonists, init
  • T446X5DAdverse effect of alpha-adrenoreceptor antagonists, subs
  • T446X5SAdverse effect of alpha-adrenoreceptor antagonists, sequela
  • T446X6AUnderdosing of alpha-adrenoreceptor antagonists, init encntr
  • T446X6DUnderdosing of alpha-adrenoreceptor antagonists, subs encntr
  • T446X6SUnderdosing of alpha-adrenoreceptor antagonists, sequela
  • T447X5AAdverse effect of beta-adrenoreceptor antagonists, init
  • T447X5DAdverse effect of beta-adrenoreceptor antagonists, subs
  • T447X5SAdverse effect of beta-adrenoreceptor antagonists, sequela
  • T447X6AUnderdosing of beta-adrenoreceptor antagonists, init encntr
  • T447X6DUnderdosing of beta-adrenoreceptor antagonists, subs encntr
  • T447X6SUnderdosing of beta-adrenoreceptor antagonists, sequela
  • T448X5AAdverse effect of centr-acting/adren-neurn-block agnt, init
  • T448X5DAdverse effect of centr-acting/adren-neurn-block agnt, subs
  • T448X5SAdvrs effect of centr-acting/adren-neurn-block agnt, sequela
  • T448X6AUnderdosing of centr-acting/adren-neurn-block agnt, init
  • T448X6DUnderdosing of centr-acting/adren-neurn-block agnt, subs
  • T448X6SUnderdosing of centr-acting/adren-neurn-block agnt, sequela
  • T44905AAdvrs effect of unsp drugs aff the autonm nervous sys, init
  • T44905DAdvrs effect of unsp drugs aff the autonm nervous sys, subs
  • T44905SAdvrs effect of unsp drugs aff the autonm nrv sys, sequela
  • T44906AUndrdose of unsp drugs aff the autonomic nervous sys, init
  • T44906DUndrdose of unsp drugs aff the autonomic nervous sys, subs
  • T44906SUndrdose of unsp drugs aff the autonm nervous sys, sequela
  • T44995AAdverse effect of drug aff the autonomic nervous sys, init
  • T44995DAdverse effect of drug aff the autonomic nervous sys, subs
  • T44995SAdverse effect of drug aff the autonm nervous sys, sequela
  • T44996AUnderdosing of drug aff the autonomic nervous system, init
  • T44996DUnderdosing of drug aff the autonomic nervous system, subs
  • T44996SUnderdosing of drug aff the autonomic nervous sys, sequela
  • T450X5AAdverse effect of antiallergic and antiemetic drugs, init
  • T450X5DAdverse effect of antiallergic and antiemetic drugs, subs
  • T450X5SAdverse effect of antiallergic and antiemetic drugs, sequela
  • T450X6AUnderdosing of antiallergic and antiemetic drugs, init
  • T450X6DUnderdosing of antiallergic and antiemetic drugs, subs
  • T450X6SUnderdosing of antiallergic and antiemetic drugs, sequela
  • T451X5AAdverse effect of antineoplastic and immunosup drugs, init
  • T451X5DAdverse effect of antineoplastic and immunosup drugs, subs
  • T451X5SAdverse effect of antineopl and immunosup drugs, sequela
  • T451X6AUnderdosing of antineoplastic and immunosup drugs, init
  • T451X6DUnderdosing of antineoplastic and immunosup drugs, subs
  • T451X6SUnderdosing of antineoplastic and immunosup drugs, sequela
  • T452X5AAdverse effect of vitamins, initial encounter
  • T452X5DAdverse effect of vitamins, subsequent encounter
  • T452X5SAdverse effect of vitamins, sequela
  • T452X6AUnderdosing of vitamins, initial encounter
  • T452X6DUnderdosing of vitamins, subsequent encounter
  • T452X6SUnderdosing of vitamins, sequela
  • T453X5AAdverse effect of enzymes, initial encounter
  • T453X5DAdverse effect of enzymes, subsequent encounter
  • T453X5SAdverse effect of enzymes, sequela
  • T453X6AUnderdosing of enzymes, initial encounter
  • T453X6DUnderdosing of enzymes, subsequent encounter
  • T453X6SUnderdosing of enzymes, sequela
  • T454X5AAdverse effect of iron and its compounds, initial encounter
  • T454X5DAdverse effect of iron and its compounds, subs encntr
  • T454X5SAdverse effect of iron and its compounds, sequela
  • T454X6AUnderdosing of iron and its compounds, initial encounter
  • T454X6DUnderdosing of iron and its compounds, subsequent encounter
  • T454X6SUnderdosing of iron and its compounds, sequela
  • T45515AAdverse effect of anticoagulants, initial encounter
  • T45515DAdverse effect of anticoagulants, subsequent encounter
  • T45515SAdverse effect of anticoagulants, sequela
  • T45516AUnderdosing of anticoagulants, initial encounter
  • T45516DUnderdosing of anticoagulants, subsequent encounter
  • T45516SUnderdosing of anticoagulants, sequela
  • T45525AAdverse effect of antithrombotic drugs, initial encounter
  • T45525DAdverse effect of antithrombotic drugs, subsequent encounter
  • T45525SAdverse effect of antithrombotic drugs, sequela
  • T45526AUnderdosing of antithrombotic drugs, initial encounter
  • T45526DUnderdosing of antithrombotic drugs, subsequent encounter
  • T45526SUnderdosing of antithrombotic drugs, sequela
  • T45605AAdverse effect of unsp fibrinolysis-affecting drugs, init
  • T45605DAdverse effect of unsp fibrinolysis-affecting drugs, subs
  • T45605SAdverse effect of unsp fibrinolysis-affecting drugs, sequela
  • T45606AUnderdosing of unsp fibrinolysis-affecting drugs, init
  • T45606DUnderdosing of unsp fibrinolysis-affecting drugs, subs
  • T45606SUnderdosing of unsp fibrinolysis-affecting drugs, sequela
  • T45615AAdverse effect of thrombolytic drugs, initial encounter
  • T45615DAdverse effect of thrombolytic drugs, subsequent encounter
  • T45615SAdverse effect of thrombolytic drugs, sequela
  • T45616AUnderdosing of thrombolytic drugs, initial encounter
  • T45616DUnderdosing of thrombolytic drugs, subsequent encounter
  • T45616SUnderdosing of thrombolytic drugs, sequela
  • T45625AAdverse effect of hemostatic drug, initial encounter
  • T45625DAdverse effect of hemostatic drug, subsequent encounter
  • T45625SAdverse effect of hemostatic drug, sequela
  • T45626AUnderdosing of hemostatic drugs, initial encounter
  • T45626DUnderdosing of hemostatic drugs, subsequent encounter
  • T45626SUnderdosing of hemostatic drugs, sequela
  • T45695AAdverse effect of oth fibrinolysis-affecting drugs, init
  • T45695DAdverse effect of oth fibrinolysis-affecting drugs, subs
  • T45695SAdverse effect of oth fibrinolysis-affecting drugs, sequela
  • T45696AUnderdosing of oth fibrinolysis-affecting drugs, init encntr
  • T45696DUnderdosing of oth fibrinolysis-affecting drugs, subs encntr
  • T45696SUnderdosing of other fibrinolysis-affecting drugs, sequela
  • T457X5AAdverse effect of anticoag antag, vit K and oth coag, init
  • T457X5DAdverse effect of anticoag antag, vit K and oth coag, subs
  • T457X5SAdvrs effect of anticoag antag, vit K and oth coag, sequela
  • T457X6AUndrdose of anticoag antagonist, vit K and oth coag, init
  • T457X6DUndrdose of anticoag antagonist, vit K and oth coag, subs
  • T457X6SUndrdose of anticoag antagonist, vit K and oth coag, sequela
  • T458X5AAdverse effect of prim systemic and hematolog agents, init
  • T458X5DAdverse effect of prim systemic and hematolog agents, subs
  • T458X5SAdverse effect of prim sys and hematolog agents, sequela
  • T458X6AUnderdosing of primarily systemic and hematolog agents, init
  • T458X6DUnderdosing of primarily systemic and hematolog agents, subs
  • T458X6SUndrdose of primarily systemic and hematolog agents, sequela
  • T4595XAAdverse effect of unsp prim sys and hematolog agent, init
  • T4595XDAdverse effect of unsp prim sys and hematolog agent, subs
  • T4595XSAdverse effect of unsp prim sys and hematolog agent, sequela
  • T4596XAUndrdose of unsp prim systemic and hematolog agent, init
  • T4596XDUndrdose of unsp prim systemic and hematolog agent, subs
  • T4596XSUndrdose of unsp prim systemic and hematolog agent, sequela
  • T460X5AAdverse effect of cardi-stim glycos/drug simlar act, init
  • T460X5DAdverse effect of cardi-stim glycos/drug simlar act, subs
  • T460X5SAdverse effect of cardi-stim glycos/drug simlar act, sequela
  • T460X6AUnderdosing of cardi-stim glycos/drug simlar act, init
  • T460X6DUnderdosing of cardi-stim glycos/drug simlar act, subs
  • T460X6SUnderdosing of cardi-stim glycos/drug simlar act, sequela
  • T461X5AAdverse effect of calcium-channel blockers, init encntr
  • T461X5DAdverse effect of calcium-channel blockers, subs encntr
  • T461X5SAdverse effect of calcium-channel blockers, sequela
  • T461X6AUnderdosing of calcium-channel blockers, initial encounter
  • T461X6DUnderdosing of calcium-channel blockers, subs encntr
  • T461X6SUnderdosing of calcium-channel blockers, sequela
  • T462X5AAdverse effect of other antidysrhythmic drugs, init encntr
  • T462X5DAdverse effect of other antidysrhythmic drugs, subs encntr
  • T462X5SAdverse effect of other antidysrhythmic drugs, sequela
  • T462X6AUnderdosing of other antidysrhythmic drugs, init encntr
  • T462X6DUnderdosing of other antidysrhythmic drugs, subs encntr
  • T462X6SUnderdosing of other antidysrhythmic drugs, sequela
  • T463X5AAdverse effect of coronary vasodilators, initial encounter
  • T463X5DAdverse effect of coronary vasodilators, subs encntr
  • T463X5SAdverse effect of coronary vasodilators, sequela
  • T463X6AUnderdosing of coronary vasodilators, initial encounter
  • T463X6DUnderdosing of coronary vasodilators, subsequent encounter
  • T463X6SUnderdosing of coronary vasodilators, sequela
  • T464X5AAdverse effect of angiotens-convert-enzyme inhibitors, init
  • T464X5DAdverse effect of angiotens-convert-enzyme inhibitors, subs
  • T464X5SAdverse effect of angiotens-convert-enzyme inhibtr, sequela
  • T464X6AUnderdosing of angiotens-convert-enzyme inhibitors, init
  • T464X6DUnderdosing of angiotens-convert-enzyme inhibitors, subs
  • T464X6SUnderdosing of angiotens-convert-enzyme inhibitors, sequela
  • T465X5AAdverse effect of other antihypertensive drugs, init encntr
  • T465X5DAdverse effect of other antihypertensive drugs, subs encntr
  • T465X5SAdverse effect of other antihypertensive drugs, sequela
  • T465X6AUnderdosing of other antihypertensive drugs, init encntr
  • T465X6DUnderdosing of other antihypertensive drugs, subs encntr
  • T465X6SUnderdosing of other antihypertensive drugs, sequela
  • T466X5AAdverse effect of antihyperlip and antiarterio drugs, init
  • T466X5DAdverse effect of antihyperlip and antiarterio drugs, subs
  • T466X5SAdvrs effect of antihyperlip and antiarterio drugs, sequela
  • T466X6AUnderdosing of antihyperlip and antiarterio drugs, init
  • T466X6DUnderdosing of antihyperlip and antiarterio drugs, subs
  • T466X6SUnderdosing of antihyperlip and antiarterio drugs, sequela
  • T467X5AAdverse effect of peripheral vasodilators, initial encounter
  • T467X5DAdverse effect of peripheral vasodilators, subs encntr
  • T467X5SAdverse effect of peripheral vasodilators, sequela
  • T467X6AUnderdosing of peripheral vasodilators, initial encounter
  • T467X6DUnderdosing of peripheral vasodilators, subsequent encounter
  • T467X6SUnderdosing of peripheral vasodilators, sequela
  • T468X5AAdverse effect of antivaric drugs, inc scler agents, init
  • T468X5DAdverse effect of antivaric drugs, inc scler agents, subs
  • T468X5SAdverse effect of antivaric drugs, inc scler agents, sequela
  • T468X6AUndrdose of antivaric drugs, including scler agents, init
  • T468X6DUndrdose of antivaric drugs, including scler agents, subs
  • T468X6SUndrdose of antivaric drugs, including scler agents, sequela
  • T46905AAdverse effect of unsp agents aff the cardiovasc sys, init
  • T46905DAdverse effect of unsp agents aff the cardiovasc sys, subs
  • T46905SAdvrs effect of unsp agents aff the cardiovasc sys, sequela
  • T46906AUnderdosing of unsp agents aff the cardiovascular sys, init
  • T46906DUnderdosing of unsp agents aff the cardiovascular sys, subs
  • T46906SUnderdosing of unsp agents aff the cardiovasc sys, sequela
  • T46995AAdverse effect of agents aff the cardiovascular sys, init
  • T46995DAdverse effect of agents aff the cardiovascular sys, subs
  • T46995SAdverse effect of agents aff the cardiovascular sys, sequela
  • T46996AUnderdosing of agents aff the cardiovascular sys, init
  • T46996DUnderdosing of agents aff the cardiovascular sys, subs
  • T46996SUnderdosing of agents aff the cardiovascular sys, sequela
  • T470X5AAdverse effect of histamine H2-receptor blockers, init
  • T470X5DAdverse effect of histamine H2-receptor blockers, subs
  • T470X5SAdverse effect of histamine H2-receptor blockers, sequela
  • T470X6AUnderdosing of histamine H2-receptor blockers, init encntr
  • T470X6DUnderdosing of histamine H2-receptor blockers, subs encntr
  • T470X6SUnderdosing of histamine H2-receptor blockers, sequela
  • T471X5AAdverse effect of antacids and anti-gstrc-sec drugs, init
  • T471X5DAdverse effect of antacids and anti-gstrc-sec drugs, subs
  • T471X5SAdverse effect of antacids and anti-gstrc-sec drugs, sequela
  • T471X6AUnderdosing of antacids and anti-gstrc-sec drugs, init
  • T471X6DUnderdosing of antacids and anti-gstrc-sec drugs, subs
  • T471X6SUnderdosing of antacids and anti-gstrc-sec drugs, sequela
  • T472X5AAdverse effect of stimulant laxatives, initial encounter
  • T472X5DAdverse effect of stimulant laxatives, subsequent encounter
  • T472X5SAdverse effect of stimulant laxatives, sequela
  • T472X6AUnderdosing of stimulant laxatives, initial encounter
  • T472X6DUnderdosing of stimulant laxatives, subsequent encounter
  • T472X6SUnderdosing of stimulant laxatives, sequela
  • T473X5AAdverse effect of saline and osmotic laxatives, init encntr
  • T473X5DAdverse effect of saline and osmotic laxatives, subs encntr
  • T473X5SAdverse effect of saline and osmotic laxatives, sequela
  • T473X6AUnderdosing of saline and osmotic laxatives, init encntr
  • T473X6DUnderdosing of saline and osmotic laxatives, subs encntr
  • T473X6SUnderdosing of saline and osmotic laxatives, sequela
  • T474X5AAdverse effect of other laxatives, initial encounter
  • T474X5DAdverse effect of other laxatives, subsequent encounter
  • T474X5SAdverse effect of other laxatives, sequela
  • T474X6AUnderdosing of other laxatives, initial encounter
  • T474X6DUnderdosing of other laxatives, subsequent encounter
  • T474X6SUnderdosing of other laxatives, sequela
  • T475X5AAdverse effect of digestants, initial encounter
  • T475X5DAdverse effect of digestants, subsequent encounter
  • T475X5SAdverse effect of digestants, sequela
  • T475X6AUnderdosing of digestants, initial encounter
  • T475X6DUnderdosing of digestants, subsequent encounter
  • T475X6SUnderdosing of digestants, sequela
  • T476X5AAdverse effect of antidiarrheal drugs, initial encounter
  • T476X5DAdverse effect of antidiarrheal drugs, subsequent encounter
  • T476X5SAdverse effect of antidiarrheal drugs, sequela
  • T476X6AUnderdosing of antidiarrheal drugs, initial encounter
  • T476X6DUnderdosing of antidiarrheal drugs, subsequent encounter
  • T476X6SUnderdosing of antidiarrheal drugs, sequela
  • T477X5AAdverse effect of emetics, initial encounter
  • T477X5DAdverse effect of emetics, subsequent encounter
  • T477X5SAdverse effect of emetics, sequela
  • T477X6AUnderdosing of emetics, initial encounter
  • T477X6DUnderdosing of emetics, subsequent encounter
  • T477X6SUnderdosing of emetics, sequela
  • T478X5AAdverse effect of agents primarily affecting GI sys, init
  • T478X5DAdverse effect of agents primarily affecting GI sys, subs
  • T478X5SAdverse effect of agents primarily affecting GI sys, sequela
  • T478X6AUnderdosing of agents primarily affecting GI sys, init
  • T478X6DUnderdosing of agents primarily affecting GI sys, subs
  • T478X6SUnderdosing of agents primarily affecting GI sys, sequela
  • T4795XAAdverse effect of unsp agents aff the GI sys, init
  • T4795XDAdverse effect of unsp agents aff the GI sys, subs
  • T4795XSAdverse effect of unsp agents aff the GI sys, sequela
  • T4796XAUnderdosing of unsp agents aff the GI sys, init
  • T4796XDUnderdosing of unsp agents aff the GI sys, subs
  • T4796XSUnderdosing of unsp agents aff the GI sys, sequela
  • T480X5AAdverse effect of oxytocic drugs, initial encounter
  • T480X5DAdverse effect of oxytocic drugs, subsequent encounter
  • T480X5SAdverse effect of oxytocic drugs, sequela
  • T480X6AUnderdosing of oxytocic drugs, initial encounter
  • T480X6DUnderdosing of oxytocic drugs, subsequent encounter
  • T480X6SUnderdosing of oxytocic drugs, sequela
  • T481X5AAdverse effect of skeletal muscle relaxants, init encntr
  • T481X5DAdverse effect of skeletal muscle relaxants, subs encntr
  • T481X5SAdverse effect of skeletal muscle relaxants, sequela
  • T481X6AUnderdosing of skeletal muscle relaxants, initial encounter
  • T481X6DUnderdosing of skeletal muscle relaxants, subs encntr
  • T481X6SUnderdosing of skeletal muscle relaxants, sequela
  • T48205AAdverse effect of unsp drugs acting on muscles, init encntr
  • T48205DAdverse effect of unsp drugs acting on muscles, subs encntr
  • T48205SAdverse effect of unsp drugs acting on muscles, sequela
  • T48206AUnderdosing of unsp drugs acting on muscles, init encntr
  • T48206DUnderdosing of unsp drugs acting on muscles, subs encntr
  • T48206SUnderdosing of unspecified drugs acting on muscles, sequela
  • T48295AAdverse effect of other drugs acting on muscles, init encntr
  • T48295DAdverse effect of other drugs acting on muscles, subs encntr
  • T48295SAdverse effect of other drugs acting on muscles, sequela
  • T48296AUnderdosing of other drugs acting on muscles, init encntr
  • T48296DUnderdosing of other drugs acting on muscles, subs encntr
  • T48296SUnderdosing of other drugs acting on muscles, sequela
  • T483X5AAdverse effect of antitussives, initial encounter
  • T483X5DAdverse effect of antitussives, subsequent encounter
  • T483X5SAdverse effect of antitussives, sequela
  • T483X6AUnderdosing of antitussives, initial encounter
  • T483X6DUnderdosing of antitussives, subsequent encounter
  • T483X6SUnderdosing of antitussives, sequela
  • T484X5AAdverse effect of expectorants, initial encounter
  • T484X5DAdverse effect of expectorants, subsequent encounter
  • T484X5SAdverse effect of expectorants, sequela
  • T484X6AUnderdosing of expectorants, initial encounter
  • T484X6DUnderdosing of expectorants, subsequent encounter
  • T484X6SUnderdosing of expectorants, sequela
  • T485X5AAdverse effect of other anti-common-cold drugs, init encntr
  • T485X5DAdverse effect of other anti-common-cold drugs, subs encntr
  • T485X5SAdverse effect of other anti-common-cold drugs, sequela
  • T485X6AUnderdosing of other anti-common-cold drugs, init encntr
  • T485X6DUnderdosing of other anti-common-cold drugs, subs encntr
  • T485X6SUnderdosing of other anti-common-cold drugs, sequela
  • T486X5AAdverse effect of antiasthmatics, initial encounter
  • T486X5DAdverse effect of antiasthmatics, subsequent encounter
  • T486X5SAdverse effect of antiasthmatics, sequela
  • T486X6AUnderdosing of antiasthmatics, initial encounter
  • T486X6DUnderdosing of antiasthmatics, subsequent encounter
  • T486X6SUnderdosing of antiasthmatics, sequela
  • T48905AAdvrs effect of unsp agents prim act on the resp sys, init
  • T48905DAdvrs effect of unsp agents prim act on the resp sys, subs
  • T48905SAdvrs effect of unsp agents prim act on the resp sys, sqla
  • T48906AUndrdose of unsp agents prim acting on the resp sys, init
  • T48906DUndrdose of unsp agents prim acting on the resp sys, subs
  • T48906SUndrdose of unsp agents prim acting on the resp sys, sequela
  • T48995AAdverse effect of agents prim acting on the resp sys, init
  • T48995DAdverse effect of agents prim acting on the resp sys, subs
  • T48995SAdvrs effect of agents prim acting on the resp sys, sequela
  • T48996AUnderdosing of agents primarily acting on the resp sys, init
  • T48996DUnderdosing of agents primarily acting on the resp sys, subs
  • T48996SUndrdose of agents primarily acting on the resp sys, sequela
  • T490X5AAdverse effect of local antifung/infect/inflamm drugs, init
  • T490X5DAdverse effect of local antifung/infect/inflamm drugs, subs
  • T490X5SAdvrs effect of local antifung/infect/inflamm drugs, sequela
  • T490X6AUnderdosing of local antifung/infect/inflamm drugs, init
  • T490X6DUnderdosing of local antifung/infect/inflamm drugs, subs
  • T490X6SUnderdosing of local antifung/infect/inflamm drugs, sequela
  • T491X5AAdverse effect of antipruritics, initial encounter
  • T491X5DAdverse effect of antipruritics, subsequent encounter
  • T491X5SAdverse effect of antipruritics, sequela
  • T491X6AUnderdosing of antipruritics, initial encounter
  • T491X6DUnderdosing of antipruritics, subsequent encounter
  • T491X6SUnderdosing of antipruritics, sequela
  • T492X5AAdverse effect of local astringents/detergents, init
  • T492X5DAdverse effect of local astringents/detergents, subs
  • T492X5SAdverse effect of local astringents/detergents, sequela
  • T492X6AUnderdosing of local astringents and local detergents, init
  • T492X6DUnderdosing of local astringents and local detergents, subs
  • T492X6SUnderdosing of local astringents/detergents, sequela
  • T493X5AAdverse effect of emollients, demulcents and protect, init
  • T493X5DAdverse effect of emollients, demulcents and protect, subs
  • T493X5SAdvrs effect of emollients, demulcents and protect, sequela
  • T493X6AUnderdosing of emollients, demulcents and protectants, init
  • T493X6DUnderdosing of emollients, demulcents and protectants, subs
  • T493X6SUnderdosing of emollients, demulcents and protect, sequela
  • T494X5AAdverse effect of keratolyt/keratplst/hair trmt drug, init
  • T494X5DAdverse effect of keratolyt/keratplst/hair trmt drug, subs
  • T494X5SAdvrs effect of keratolyt/keratplst/hair trmt drug, sequela
  • T494X6AUnderdosing of keratolyt/keratplst/hair trmt drug, init
  • T494X6DUnderdosing of keratolyt/keratplst/hair trmt drug, subs
  • T494X6SUnderdosing of keratolyt/keratplst/hair trmt drug, sequela
  • T495X5AAdverse effect of opth drugs and preparations, init
  • T495X5DAdverse effect of opth drugs and preparations, subs
  • T495X5SAdverse effect of opth drugs and preparations, sequela
  • T495X6AUnderdosing of ophthalmological drugs and preparations, init
  • T495X6DUnderdosing of ophthalmological drugs and preparations, subs
  • T495X6SUnderdosing of opth drugs and preparations, sequela
  • T496X5AAdverse effect of otorhino drugs and preparations, init
  • T496X5DAdverse effect of otorhino drugs and preparations, subs
  • T496X5SAdverse effect of otorhino drugs and preparations, sequela
  • T496X6AUnderdosing of otorhino drugs and preparations, init
  • T496X6DUnderdosing of otorhino drugs and preparations, subs
  • T496X6SUnderdosing of otorhino drugs and preparations, sequela
  • T497X5AAdverse effect of dental drugs, topically applied, init
  • T497X5DAdverse effect of dental drugs, topically applied, subs
  • T497X5SAdverse effect of dental drugs, topically applied, sequela
  • T497X6AUnderdosing of dental drugs, topically applied, init encntr
  • T497X6DUnderdosing of dental drugs, topically applied, subs encntr
  • T497X6SUnderdosing of dental drugs, topically applied, sequela
  • T498X5AAdverse effect of other topical agents, initial encounter
  • T498X5DAdverse effect of other topical agents, subsequent encounter
  • T498X5SAdverse effect of other topical agents, sequela
  • T498X6AUnderdosing of other topical agents, initial encounter
  • T498X6DUnderdosing of other topical agents, subsequent encounter
  • T498X6SUnderdosing of other topical agents, sequela
  • T4995XAAdverse effect of unspecified topical agent, init encntr
  • T4995XDAdverse effect of unspecified topical agent, subs encntr
  • T4995XSAdverse effect of unspecified topical agent, sequela
  • T4996XAUnderdosing of unspecified topical agent, initial encounter
  • T4996XDUnderdosing of unspecified topical agent, subs encntr
  • T4996XSUnderdosing of unspecified topical agent, sequela
  • T500X5AAdverse effect of mineralocorticoids and their antag, init
  • T500X5DAdverse effect of mineralocorticoids and their antag, subs
  • T500X5SAdverse effect of mineralocorticoids and antag, sequela
  • T500X6AUnderdosing of mineralocorticoids and their antag, init
  • T500X6DUnderdosing of mineralocorticoids and their antag, subs
  • T500X6SUnderdosing of mineralocorticoids and their antag, sequela
  • T501X5AAdverse effect of loop diuretics, initial encounter
  • T501X5DAdverse effect of loop diuretics, subsequent encounter
  • T501X5SAdverse effect of loop [high-ceiling] diuretics, sequela
  • T501X6AUnderdosing of loop diuretics, initial encounter
  • T501X6DUnderdosing of loop diuretics, subsequent encounter
  • T501X6SUnderdosing of loop [high-ceiling] diuretics, sequela
  • T502X5AAdvrs eff of crbnc-anhydr inhibtr, benzo/oth diuretc, init
  • T502X5DAdvrs eff of crbnc-anhydr inhibtr, benzo/oth diuretc, subs
  • T502X5SAdvrs eff of crbnc-anhydr inhibtr, benzo/oth diuretc, sqla
  • T502X6AUnderdosing of crbnc-anhydr inhibtr, benzo/oth diuretc, init
  • T502X6DUnderdosing of crbnc-anhydr inhibtr, benzo/oth diuretc, subs
  • T502X6SUndrdose of crbnc-anhydr inhibtr, benzo/oth diuretc, sequela
  • T503X5AAdverse effect of electrolytic/caloric/wtr-bal agnt, init
  • T503X5DAdverse effect of electrolytic/caloric/wtr-bal agnt, subs
  • T503X5SAdverse effect of electrolytic/caloric/wtr-bal agnt, sequela
  • T503X6AUnderdosing of electrolytic/caloric/wtr-bal agnt, init
  • T503X6DUnderdosing of electrolytic/caloric/wtr-bal agnt, subs
  • T503X6SUnderdosing of electrolytic/caloric/wtr-bal agnt, sequela
  • T504X5AAdverse effect of drugs affecting uric acid metabolism, init
  • T504X5DAdverse effect of drugs affecting uric acid metabolism, subs
  • T504X5SAdverse effect of drugs affecting uric acid metab, sequela
  • T504X6AUnderdosing of drugs affecting uric acid metabolism, init
  • T504X6DUnderdosing of drugs affecting uric acid metabolism, subs
  • T504X6SUnderdosing of drugs affecting uric acid metabolism, sequela
  • T505X5AAdverse effect of appetite depressants, initial encounter
  • T505X5DAdverse effect of appetite depressants, subsequent encounter
  • T505X5SAdverse effect of appetite depressants, sequela
  • T505X6AUnderdosing of appetite depressants, initial encounter
  • T505X6DUnderdosing of appetite depressants, subsequent encounter
  • T505X6SUnderdosing of appetite depressants, sequela
  • T506X5AAdverse effect of antidotes and chelating agents, init
  • T506X5DAdverse effect of antidotes and chelating agents, subs
  • T506X5SAdverse effect of antidotes and chelating agents, sequela
  • T506X6AUnderdosing of antidotes and chelating agents, init encntr
  • T506X6DUnderdosing of antidotes and chelating agents, subs encntr
  • T506X6SUnderdosing of antidotes and chelating agents, sequela
  • T507X5AAdverse effect of analeptics and opioid receptor antag, init
  • T507X5DAdverse effect of analeptics and opioid receptor antag, subs
  • T507X5SAdvrs effect of analeptics and opioid receptor antag, sqla
  • T507X6AUnderdosing of analeptics and opioid receptor antag, init
  • T507X6DUnderdosing of analeptics and opioid receptor antag, subs
  • T507X6SUnderdosing of analeptics and opioid receptor antag, sequela
  • T508X5AAdverse effect of diagnostic agents, initial encounter
  • T508X5DAdverse effect of diagnostic agents, subsequent encounter
  • T508X5SAdverse effect of diagnostic agents, sequela
  • T508X6AUnderdosing of diagnostic agents, initial encounter
  • T508X6DUnderdosing of diagnostic agents, subsequent encounter
  • T508X6SUnderdosing of diagnostic agents, sequela
  • T50915AAdverse effect of multiple unsp drug/meds/biol subst, init
  • T50915DAdverse effect of multiple unsp drug/meds/biol subst, subs
  • T50915SAdverse effect of mult unsp drug/meds/biol subst, sequela
  • T50916AUndrdose of multiple unspecified drug/meds/biol subst, init
  • T50916DUndrdose of multiple unspecified drug/meds/biol subst, subs
  • T50916SUndrdose of multiple unsp drug/meds/biol subst, sequela
  • T50A15AAdvrs effect of pertuss vaccine, inc combin w pertuss, init
  • T50A15DAdvrs effect of pertuss vaccine, inc combin w pertuss, subs
  • T50A15SAdvrs effect of pertuss vaccine, inc combin w pertuss, sqla
  • T50A16AUndrdose of pertussis vaccine, inc combin w pertuss, init
  • T50A16DUndrdose of pertussis vaccine, inc combin w pertuss, subs
  • T50A16SUndrdose of pertussis vaccine, inc combin w pertuss, sequela
  • T50A25AAdverse effect of mixed bact vaccines w/o a pertuss, init
  • T50A25DAdverse effect of mixed bact vaccines w/o a pertuss, subs
  • T50A25SAdverse effect of mixed bact vaccines w/o a pertuss, sequela
  • T50A26AUnderdosing of mixed bacterial vaccines w/o a pertuss, init
  • T50A26DUnderdosing of mixed bacterial vaccines w/o a pertuss, subs
  • T50A26SUndrdose of mixed bacterial vaccines w/o a pertuss, sequela
  • T50A95AAdverse effect of other bacterial vaccines, init encntr
  • T50A95DAdverse effect of other bacterial vaccines, subs encntr
  • T50A95SAdverse effect of other bacterial vaccines, sequela
  • T50A96AUnderdosing of other bacterial vaccines, initial encounter
  • T50A96DUnderdosing of other bacterial vaccines, subs encntr
  • T50A96SUnderdosing of other bacterial vaccines, sequela
  • T50B15AAdverse effect of smallpox vaccines, initial encounter
  • T50B15DAdverse effect of smallpox vaccines, subsequent encounter
  • T50B15SAdverse effect of smallpox vaccines, sequela
  • T50B16AUnderdosing of smallpox vaccines, initial encounter
  • T50B16DUnderdosing of smallpox vaccines, subsequent encounter
  • T50B16SUnderdosing of smallpox vaccines, sequela
  • T50B95AAdverse effect of other viral vaccines, initial encounter
  • T50B95DAdverse effect of other viral vaccines, subsequent encounter
  • T50B95SAdverse effect of other viral vaccines, sequela
  • T50B96AUnderdosing of other viral vaccines, initial encounter
  • T50B96DUnderdosing of other viral vaccines, subsequent encounter
  • T50B96SUnderdosing of other viral vaccines, sequela
  • T50Z15AAdverse effect of immunoglobulin, initial encounter
  • T50Z15DAdverse effect of immunoglobulin, subsequent encounter
  • T50Z15SAdverse effect of immunoglobulin, sequela
  • T50Z16AUnderdosing of immunoglobulin, initial encounter
  • T50Z16DUnderdosing of immunoglobulin, subsequent encounter
  • T50Z16SUnderdosing of immunoglobulin, sequela
  • T50Z95AAdverse effect of vaccines and biological substances, init
  • T50Z95DAdverse effect of vaccines and biological substances, subs
  • T50Z95SAdverse effect of vaccines and biolg substances, sequela
  • T50Z96AUnderdosing of oth vaccines and biological substances, init
  • T50Z96DUnderdosing of oth vaccines and biological substances, subs
  • T50Z96SUnderdosing of vaccines and biological substances, sequela
  • T8112XAPostprocedural septic shock, initial encounter
  • T8112XDPostprocedural septic shock, subsequent encounter
  • T8112XSPostprocedural septic shock, sequela
  • Z1505Genetic susceptibility to malignant neoplasm of fallop(s)
  • Z15060Genetic susceptibility to colorectal cancer
  • Z15068Genetic susceptibility to other malig neoplasm of dgstv sys
  • Z1507Genetic susceptibility to malig neoplasm of urinary tract
  • Z153Genetic susceptibility to kidney disease
  • Z1610Resistance to unspecified beta lactam antibiotics
  • Z1611Resistance to penicillins
  • Z1612Extended spectrum beta lactamase (ESBL) resistance
  • Z1613Resistance to carbapenem
  • Z1619Resistance to other specified beta lactam antibiotics
  • Z1620Resistance to unspecified antibiotic
  • Z1621Resistance to vancomycin
  • Z1622Resistance to vancomycin related antibiotics
  • Z1623Resistance to quinolones and fluoroquinolones
  • Z1624Resistance to multiple antibiotics
  • Z1629Resistance to other single specified antibiotic
  • Z1630Resistance to unspecified antimicrobial drugs
  • Z1631Resistance to antiparasitic drug(s)
  • Z1632Resistance to antifungal drug(s)
  • Z1633Resistance to antiviral drug(s)
  • Z16341Resistance to single antimycobacterial drug
  • Z16342Resistance to multiple antimycobacterial drugs
  • Z1635Resistance to multiple antimicrobial drugs
  • Z1639Resistance to other specified antimicrobial drug
  • Z170Estrogen receptor positive status [ER+]
  • Z171Estrogen receptor negative status [ER-]
  • Z1721Progesterone receptor positive status
  • Z1722Progesterone receptor negative status
  • Z191Hormone sensitive malignancy status
  • Z192Hormone resistant malignancy status
  • Z28310Unvaccinated for COVID-19
  • Z28311Partially vaccinated for COVID-19
  • Z2839Other underimmunization status
  • Z370Single live birth
  • Z371Single stillbirth
  • Z372Twins, both liveborn
  • Z373Twins, one liveborn and one stillborn
  • Z374Twins, both stillborn
  • Z3750Multiple births, unspecified, all liveborn
  • Z3751Triplets, all liveborn
  • Z3752Quadruplets, all liveborn
  • Z3753Quintuplets, all liveborn
  • Z3754Sextuplets, all liveborn
  • Z3759Other multiple births, all liveborn
  • Z3760Multiple births, unspecified, some liveborn
  • Z3761Triplets, some liveborn
  • Z3762Quadruplets, some liveborn
  • Z3763Quintuplets, some liveborn
  • Z3764Sextuplets, some liveborn
  • Z3769Other multiple births, some liveborn
  • Z377Other multiple births, all stillborn
  • Z379Outcome of delivery, unspecified
  • Z3A00Weeks of gestation of pregnancy not specified
  • Z3A01Less than 8 weeks gestation of pregnancy
  • Z3A088 weeks gestation of pregnancy
  • Z3A099 weeks gestation of pregnancy
  • Z3A1010 weeks gestation of pregnancy
  • Z3A1111 weeks gestation of pregnancy
  • Z3A1212 weeks gestation of pregnancy
  • Z3A1313 weeks gestation of pregnancy
  • Z3A1414 weeks gestation of pregnancy
  • Z3A1515 weeks gestation of pregnancy
  • Z3A1616 weeks gestation of pregnancy
  • Z3A1717 weeks gestation of pregnancy
  • Z3A1818 weeks gestation of pregnancy
  • Z3A1919 weeks gestation of pregnancy
  • Z3A2020 weeks gestation of pregnancy
  • Z3A2121 weeks gestation of pregnancy
  • Z3A2222 weeks gestation of pregnancy
  • Z3A2323 weeks gestation of pregnancy
  • Z3A2424 weeks gestation of pregnancy
  • Z3A2525 weeks gestation of pregnancy
  • Z3A2626 weeks gestation of pregnancy
  • Z3A2727 weeks gestation of pregnancy
  • Z3A2828 weeks gestation of pregnancy
  • Z3A2929 weeks gestation of pregnancy
  • Z3A3030 weeks gestation of pregnancy
  • Z3A3131 weeks gestation of pregnancy
  • Z3A3232 weeks gestation of pregnancy
  • Z3A3333 weeks gestation of pregnancy
  • Z3A3434 weeks gestation of pregnancy
  • Z3A3535 weeks gestation of pregnancy
  • Z3A3636 weeks gestation of pregnancy
  • Z3A3737 weeks gestation of pregnancy
  • Z3A3838 weeks gestation of pregnancy
  • Z3A3939 weeks gestation of pregnancy
  • Z3A4040 weeks gestation of pregnancy
  • Z3A4141 weeks gestation of pregnancy
  • Z3A4242 weeks gestation of pregnancy
  • Z3A49Greater than 42 weeks gestation of pregnancy
  • Z4089Encounter for other prophylactic surgery
  • Z5331Laparoscopic surgical procedure converted to open procedure
  • Z5332Thoracoscopic surgical procedure converted to open procedure
  • Z5333Arthroscopic surgical procedure converted to open procedure
  • Z5339Other specified procedure converted to open procedure
  • Z555Less than a high school diploma
  • Z556Problems related to health literacy
  • Z586Inadequate drinking-water supply
  • Z5881Basic services unavailable in physical environment
  • Z5889Other problems related to physical environment
  • Z5900Homelessness unspecified
  • Z5901Sheltered homelessness
  • Z5902Unsheltered homelessness
  • Z5910Inadequate housing, unspecified
  • Z5911Inadequate housing environmental temperature
  • Z5912Inadequate housing utilities
  • Z5919Other inadequate housing
  • Z5941Food insecurity
  • Z5948Other specified lack of adequate food
  • Z5971Insufficient health insurance coverage
  • Z5972Insufficient welfare support
  • Z59811Housing instability, housed, with risk of homelessness
  • Z59812Housing instability, housed, homelessness in past 12 months
  • Z59819Housing instability, housed unspecified
  • Z5982Transportation insecurity
  • Z59861Financial insecurity, difficulty paying for utilities
  • Z59868Other specified financial insecurity
  • Z59869Financial insecurity, unspecified
  • Z5987Material hardship due to limited financial resources, NEC
  • Z5989Other problems related to housing and economic circumstances
  • Z6223Child in custody of non-parental relative
  • Z6224Child in custody of non-relative guardian
  • Z62814Personal history of child financial abuse
  • Z62815Personal history of intimate partner abuse in childhood
  • Z62823Parent-step child conflict
  • Z62831Non-parental relative-child conflict
  • Z62832Non-relative guardian-child conflict
  • Z62833Group home staff-child conflict
  • Z62892Runaway [from current living environment]
  • Z681Body mass index [BMI] 19.9 or less, adult
  • Z6820Body mass index [BMI] 20.0-20.9, adult
  • Z6821Body mass index [BMI] 21.0-21.9, adult
  • Z6822Body mass index [BMI] 22.0-22.9, adult
  • Z6823Body mass index [BMI] 23.0-23.9, adult
  • Z6824Body mass index [BMI] 24.0-24.9, adult
  • Z6825Body mass index [BMI] 25.0-25.9, adult
  • Z6826Body mass index [BMI] 26.0-26.9, adult
  • Z6827Body mass index [BMI] 27.0-27.9, adult
  • Z6828Body mass index [BMI] 28.0-28.9, adult
  • Z6829Body mass index [BMI] 29.0-29.9, adult
  • Z6830Body mass index [BMI] 30.0-30.9, adult
  • Z6831Body mass index [BMI] 31.0-31.9, adult
  • Z6832Body mass index [BMI] 32.0-32.9, adult
  • Z6833Body mass index [BMI] 33.0-33.9, adult
  • Z6834Body mass index [BMI] 34.0-34.9, adult
  • Z6835Body mass index [BMI] 35.0-35.9, adult
  • Z6836Body mass index [BMI] 36.0-36.9, adult
  • Z6837Body mass index [BMI] 37.0-37.9, adult
  • Z6838Body mass index [BMI] 38.0-38.9, adult
  • Z6839Body mass index [BMI] 39.0-39.9, adult
  • Z6841Body mass index [BMI] 40.0-44.9, adult
  • Z6842Body mass index [BMI] 45.0-49.9, adult
  • Z6843Body mass index [BMI] 50.0-59.9, adult
  • Z6844Body mass index [BMI] 60.0-69.9, adult
  • Z6845Body mass index [BMI] 70 or greater, adult
  • Z6851Body mass index pediatric, less than 5th percentile for age
  • Z6852Body mass index pediatric, 5th percentile to < 85% for age
  • Z6853Body mass index pediatric, 85% to less than 95% for age
  • Z6854Body mass index ped, 95% for age to < 120% of 95% for age
  • Z6855Body mass index ped, 120% 95% for age to < 140% 95% for age
  • Z6856Body mass index ped, > or equal to 140% of the 95% for age
  • Z72823Risk of suffocation (smothering) under another wh sleeping
  • Z7731Contact with and (suspected) exposure to Gulf War theater
  • Z7739Contact with and (suspected) exposure to other war theater
  • Z7902Long term (current) use of antithrombotics/antiplatelets
  • Z791Long term (current) use of non-steroidal non-inflam (NSAID)
  • Z792Long term (current) use of antibiotics
  • Z7951Long term (current) use of inhaled steroids
  • Z7952Long term (current) use of systemic steroids
  • Z7960Lng trm (crnt) use unsp immunomodulator & immunosuppressant
  • Z7961Long term (current) use of immunomodulator
  • Z79620Long term (current) use of immunosuppressive biologic
  • Z79621Long term (current) use of calcineurin inhibitor
  • Z79622Long term (current) use of Janus kinase inhibitor
  • Z79623Long term (crnt) use of mammalian target rapamycin inhibitor
  • Z79624Long term (current) use of inhibtr of nucleotide synthesis
  • Z79630Long term (current) use of alkylating agent
  • Z79631Long term (current) use of antimetabolite agent
  • Z79632Long term (current) use of antitumor antibiotic
  • Z79633Long term (current) use of mitotic inhibitor
  • Z79634Long term (current) use of topoisomerase inhibitor
  • Z7964Long term (current) use of myelosuppressive agent
  • Z7969Lng trm (crnt) use of immunomodulator & immunosuppressant
  • Z79810Lng trm (crnt) use of slctv estrog receptor modulators
  • Z79811Long term (current) use of aromatase inhibitors
  • Z79818Lng trm (crnt) use of agnt aff estrog recpt & estrog levels
  • Z7983Long term (current) use of bisphosphonates
  • Z7984Long term (current) use of oral hypoglycemic drugs
  • Z7985Lng trm (crnt) use injectable non-insulin antidiabetic drugs
  • Z79890Hormone replacement therapy
  • Z800Family history of malignant neoplasm of digestive organs
  • Z801Family history of malig neoplasm of trachea, bronc and lung
  • Z802Family hx of malig neoplm of resp and intrathorac organs
  • Z803Family history of malignant neoplasm of breast
  • Z8041Family history of malignant neoplasm of ovary
  • Z8042Family history of malignant neoplasm of prostate
  • Z8043Family history of malignant neoplasm of testis
  • Z8044Family history of malignant neoplasm of fallopian tube(s)
  • Z8049Family history of malignant neoplasm of other genital organs
  • Z8051Family history of malignant neoplasm of kidney
  • Z8052Family history of malignant neoplasm of bladder
  • Z8059Family history of malignant neoplasm of urinary tract organ
  • Z806Family history of leukemia
  • Z807Fam hx of malig neoplm of lymphoid, hematpoetc and rel tiss
  • Z808Family history of malignant neoplasm of organs or systems
  • Z809Family history of malignant neoplasm, unspecified
  • Z820Family history of epilepsy and oth dis of the nervous sys
  • Z821Family history of blindness and visual loss
  • Z822Family history of deafness and hearing loss
  • Z823Family history of stroke
  • Z8241Family history of sudden cardiac death
  • Z8249Family hx of ischem heart dis and oth dis of the circ sys
  • Z825Family history of asthma and oth chronic lower resp diseases
  • Z8261Family history of arthritis
  • Z8262Family history of osteoporosis
  • Z8269Family history of diseases of the ms sys and connective tiss
  • Z8271Family history of polycystic kidney
  • Z8279Fam hx of congen malform, deformations and chromsoml abnlt
  • Z828Family hx of disabil and chr dis leading to disablement, NEC
  • Z830Family history of human immunodeficiency virus [HIV] disease
  • Z831Family history of other infectious and parasitic diseases
  • Z832Family history of dis of the bld/bld-form org/immun mechnsm
  • Z833Family history of diabetes mellitus
  • Z8341Family history of multiple endocrine neoplasia syndrome
  • Z8342Family history of familial hypercholesterolemia
  • Z83430Family history of elevated lipoprotein(a)
  • Z83438Fam hx of disord of lipoprotein metab and other lipidemia
  • Z8349Family history of endo, nutritional and metabolic diseases
  • Z83511Family history of glaucoma
  • Z83518Family history of other specified eye disorder
  • Z8352Family history of ear disorders
  • Z836Family history of other diseases of the respiratory system
  • Z83710Family history of adenomatous and serrated polyps
  • Z83711Family history of hyperplastic colon polyps
  • Z83718Family history of other colon polyps
  • Z83719Family history of colon polyps, unspecified
  • Z8372Family history of familial adenomatous polyposis
  • Z8379Family history of other diseases of the digestive system
  • Z840Family history of diseases of the skin, subcu
  • Z8411Family history of APOL1-mediated kidney disease [AMKD]
  • Z8419Family history of other disorders of kidney and ureter
  • Z842Family history of other diseases of the genitourinary system
  • Z843Family history of consanguinity
  • Z8481Family history of carrier of genetic disease
  • Z8482Family history of sudden infant death syndrome
  • Z8489Family history of other specified conditions
  • Z84AFamily history of exposure to diethylstilbestrol
  • Z854APersonal history of malignant neoplasm of fallopian tube(s)
  • Z8600APers hx of in-situ neoplasm of the fallopian tube(s)
  • Z860100Personal history of colon polyps, unspecified
  • Z860101Personal history of adenomatous and serrated colon polyps
  • Z860102Personal history of hyperplastic colon polyps
  • Z860109Personal history of other colon polyps
  • Z8616Personal history of COVID-19
  • Z8761Pers hx of (corrected) necrotizing enterocolitis of newborn
  • Z8768Pers hx of other conditions arising in the perinatal period
  • Z87731Pers hx of (corrected) tracheoesophageal fistula or atresia
  • Z87732Pers hx of (corrected) persistent cloaca or cloacal malform
  • Z87760Pers hx congen diaphragm hernia/oth congen diaphragm malform
  • Z87761Personal history of (corrected) gastroschisis
  • Z87762Personal history of (corrected) prune belly malformation
  • Z87763Pers hx of other (corrected) congenital abd wall malform
  • Z87768Pers hx of oth congen malform of integument, lmbs and ms sys
  • Z910110Allergy to milk products, unspecified
  • Z910111Allergy to milk products with tolerance to baked milk
  • Z910112Allergy to milk products with reactivity to baked milk
  • Z910120Allergy to eggs, unspecified
  • Z910121Allergy to eggs with tolerance to baked egg
  • Z910122Allergy to eggs with reactivity to baked egg
  • Z91110Pt noncompl with dietary regimen due to financl hardship
  • Z91118Patient's noncompl with dietary regimen for other reason
  • Z91119Patient's noncompl with dietary regimen due to unsp reason
  • Z91141Pt other noncompl with meds regimen due to financl hardship
  • Z91148Patient's other noncompl with meds regimen for other reason
  • Z91151Pt noncompl with renal dialysis due to financl hardship
  • Z91158Patient's noncompliance with renal dialysis for other reason
  • Z91190Pt noncompl w oth med trtmt and regimen d/t financl hardship
  • Z91198Pt noncompl with other med trtmt and regimen for other rsn
  • Z91199Pt noncompl with other med trtmt and regimen d/t unsp reason
  • Z91413Personal history of adult financial abuse
  • Z91414Personal history of adult intimate partner abuse
  • Z9151Personal history of suicidal behavior
  • Z9152Personal history of nonsuicidal self-harm
  • Z9185Personal history of military service
  • Z91A10Carers noncompl with pt diet regimen due to financl hardship
  • Z91A18Carers noncompl with pt dietary regimen for other reason
  • Z91A20Carers intentl undrdose pt meds regimen d/t financl hardship
  • Z91A28Carers intentl undrdose of meds regimen for other reason
  • Z91A3Carers unintent underdosing of patient's medication regimen
  • Z91A41Carers other noncompl with pt meds regimen due to fin hrdshp
  • Z91A48Carers other noncompl with pt meds regimen for other reason
  • Z91A51Carers noncompl with pt renal dialysis due to fin hrdshp
  • Z91A58Carers noncompl with pt renal dialysis for other reason
  • Z91A91Carers noncompl w pt oth med trtmt & regimen d/t fin hrdshp
  • Z91A98Carers noncompl w pt oth med trtmt and regimen for oth rsn
  • Z91BPersonal risk factor of exposure to diethylstilbestrol
  • Z9225Personal history of immunosuppression therapy
  • Z9282S/p admn tPA in diff fac w/n last 24 hr bef adm to crnt fac
  • Z92850Personal history of Chimeric Antigen Receptor T-cell therapy
  • Z92858Personal history of other cellular therapy
  • Z92859Personal history of cellular therapy, unspecified
  • Z9286Personal history of gene therapy
  • Z983Post therapeutic collapse of lung status

Source: CMS HH PPS Grouper Software v07.1.26, UNACCEPTABLE_PDX flag in Diagnosis_Codes.txt.

The monthly home health regs digest

What CMS changed, what's due next, and what to do about it — one email a month, no fluff.